STIC Search Report
EIC 1700

USPTO

STIC Database Tracking Number: 190281

TO: Devesh Khare
Location: REM-5C35&5C18
Art Unit : 1623
June 8, 2006

Case Serial Number: 10/670915

From: Les Henderson
Location: EIC 1700
REMSEN 4B30
Phone: 571/272-2538
Leslie.Henderson@uspto.gov

Search Notes

Please scan
Thank you

sira
Search and Information Resources Administration

190351

Access DB#_____

RECEIVED
MAY 17 200
(STIC)

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester=s full Name: Devesh Khare Examiner #: 77931 Date: 05/17/2006
Art Unit: 1623 Phone Number 272-0653 Serial Number: 10/670,915
Mail Box: Remsen 5C18 and Bldg/Room Location: 5C35 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be search Include the elected species or structures, key words, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: 1,3,5-triazines for treatment of viral diseases.

Inventors (please provide full names): Richard Daifuku; Alexander Gall; and Dmitri Sergeev

Earliest priority Filing Date: 09/24/2002

Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Carry out a search on the attached claims sheet, examiner's hints provided

Thank you

STAFF USE ONLY

Searcher: _____
Searcher Phone #: _____
Searcher Location: _____
Date Searcher Picked Up: _____
Date Completed: _____
Searcher Prep & Review Time: _____
Clerical Prep time: _____
Online Time: _____

Type of Search
NA Sequence (#) _____
AA Sequence (#) _____
Structure (#) _____
Bibliographic _____
Litigation _____
Fulltext _____
Patent Family _____
Other _____

Vendors and cost where applicable
STIC-ERD (1-2006)

Rush Search Approved

Rush Search Request

STIC Search Results Feedback Form

USPTO

EIC17000

Questions about the scope or the results of the search? Contact ***the EIC searcher or contact:***

Kathleen Fuller, EIC 1700 Team Leader
571/272-2505 REMSEN 4B28

Voluntary Results Feedback Form

- *I am an examiner in Workgroup:* ☐ *Example: 1713*
- *Relevant prior art* ***found****, search results used as follows:*
  - ☐ 102 rejection
  - ☐ 103 rejection
  - ☐ Cited as being of interest.
  - ☐ Helped examiner better understand the invention.
  - ☐ Helped examiner better understand the state of the art in their technology.

Types of relevant prior art found:

- ☐ Foreign Patent(s)
- ☐ Non-Patent Literature
  (journal articles, conference proceedings, new product announcements etc.)

- *Relevant prior art* ***not found:***
  - ☐ Results verified the lack of relevant prior art (helped determine patentability).
  - ☐ Results were not useful in determining patentability or understanding the invention.

Comments:

Drop off or send completed forms to EIC1700 REMSEN 4B28

190281

Access DB#_____

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester=s full Name: Devesh Khare Examiner #: 77931 Date: 05/17/2006

Art Unit: 1623 Phone Number 272-0653 Serial Number: 10/670,915

Mail Box: Remsen 5C18 and Bldg/Room Location: 5C35 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be search Include the elected species or structures, key words, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: 1,3,5-triazines for treatment of viral diseases.

Inventors (please provide full names): Richard Daifuku; Alexander Gall; and Dmitri Sergueev.

Earliest priority Filing Date: **09/24/2002**

**For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Please carry out a search on the attached claims sheet; examiner's hints provided.

Thank you.

STAFF USE ONLY	Type of Search	Vendors and cost where applicable
Searcher: YA	NA Sequence (#)_____	STN $ 891.38
Searcher Phone #:_____	AA Sequence (#)_____	Dialog_____
Searcher Location:_____	Structure (#) 3	Questel/Orbit_____
Date Searcher Picked Up:_____	Bibliographic _____	Dr. Link_____
Date Completed: 6/8/06	Litigation _____	Lexis/Nexis_____
Searcher Prep & Review Time: 30	Fulltext _____	Sequence Systems_____
Clerical prep time: 20	Patent Family_____	WWW/Internet_____
Online Time: 230	Other _____	Other (specify)_____

PTO-1590 (1-2000)

1. A compound having the formula:



wherein

Y is a member selected from C, CH and N;

Z is a member selected from C, CH and B;

R^1 is a member selected from H, acyl, OR^9, SR^9, $NHNH_2$, NR^9R^{10}, =O and $=NR^9$, wherein

R^9 and R^{10} are members independently selected from H, substituted or unsubstituted alkyl, acyl, substituted or unsubstituted heteroalkyl and substituted or unsubstituted aryl;

R^2 is present or absent and is a member selected from H, acyl, substituted or unsubstituted alkyl, OR^{11}, SR^{11}, NR^{11a}, NR^{12a}, halogen, and =O, wherein

R^{11} is a member selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heterocycloalkyl, and substituted or unsubstituted heteroaryl;

R^{11a} and R^{12a} are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl;

R^3 is a member selected from H, acyl, substituted or unsubstituted alkyl, $NR^{12}R^{13}$, $NR^{12}OR^{13}$, SR^{12}, (=O) and OR^{12}, wherein

R^{12} and R^{13} are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl;

R^4 and R^{4a} are members independently selected from H, halogen, OMe and OH;

R^5 and R^6 are members independently selected from H, and OR^{14}, wherein

R^{14} is a member selected from H, substituted or unsubstituted alkyl, acyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl and $P(O)(R^{15})(R^{16})$, wherein

R^{15} and R^{16} are members independently selected from OR^{17}, $NR^{17}R^{18}$, OCH_2CH_2CN, substituted or unsubstituted alkyl and substituted or unsubstituted nucleosides, wherein

R^{17} and R^{18} are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl,

wherein a member selected from R^5 and R^2; R^6 and R^1; and R^{15} and R^{16} together with the atoms to which they are attached are optionally joined to form a ring system selected from substituted or unsubstituted cycloalkyl and substituted or unsubstituted heterocycloalkyl;

R^7 and R^8 are either present or absent and are independently selected from H, acyl, substituted or unsubstituted alkyl, and R^1 and R^8, together with the atoms to which they are attached are optionally joined into a ring system selected from substituted or unsubstituted cycloalkyl and substituted or unsubstituted heterocycloalkyl.

Examiner's hints and search points:

Please search the following specific compounds:

1.



2.



(III).

In an exemplary compound according to Formula III, R^{11} is cleaveable moiety, for example, a silyl group or substituted or unsubstituted alkyl ether, *e.g.*,





R, R' = H, OH

R_1, R_2, R_3 = Alkyl, Aryl or substituted alkyl

3.



(IV).

Exemplary compounds according to the Formulae above include:





; and



R, R' = H, OH
Q = Hydrophobic substituent



; and



In a further embodiment, the present invention provides a compound according to Formula V:



(V)

in which R^{19}, R^{20}, and R^{21} are members independently selected from H, acyl and substituted or unsubstituted alkyl.

And structures of claims 7 and 8:

7. The compound according to claim 5, having the formula:



8. The compound according to claim 1, wherein R^6 has the formula:



in which

R^{22} is a member selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl;

L is a linker selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl; and

Ar is a member selected from substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.

```
=> d his ful

     (FILE 'HOME' ENTERED AT 13:42:51 ON 07 JUN 2006)

     FILE 'HCAPLUS' ENTERED AT 13:43:33 ON 07 JUN 2006
                E US20040127436/PN
L1            1 SEA ABB=ON  PLU=ON  US20040127436/PN
                D ALL
                SEL RN

     FILE 'REGISTRY' ENTERED AT 13:47:40 ON 07 JUN 2006
L2           38 SEA ABB=ON  PLU=ON  (10302-79-1/BI OR 105330-91-4/BI
                OR 105330-94-7/BI OR 105330-96-9/BI OR 106206-74-0/BI
                OR 108-24-7/BI OR 114522-16-6/BI OR 114522-18-8/BI OR
                114522-19-9/BI OR 117399-73-2/BI OR 14215-97-5/BI OR
                16352-06-0/BI OR 183016-20-8/BI OR 217090-42-1/BI OR
                2353-33-5/BI OR 320-67-2/BI OR 3601-89-6/BI OR
                40789-35-3/BI OR 461-58-5/BI OR 57-10-3/BI OR 676607-90
                -2/BI OR 676607-91-3/BI OR 676607-92-4/BI OR 676607-93-
                5/BI OR 676607-94-6/BI OR 676607-95-7/BI OR 676607-96-8
                /BI OR 676607-97-9/BI OR 676607-98-0/BI OR 676607-99-1/
                BI OR 676608-00-7/BI OR 676608-01-8/BI OR 69304-37-6/BI
                 OR 79-30-1/BI OR 80646-62-4/BI OR 80646-63-5/BI OR
                80646-65-7/BI OR 9068-38-6/BI)
                D SCAN

     FILE 'LREGISTRY' ENTERED AT 13:59:52 ON 07 JUN 2006

     FILE 'REGISTRY' ENTERED AT 14:15:25 ON 07 JUN 2006
                D L2 1-38 STR RN

     FILE 'LREGISTRY' ENTERED AT 14:19:41 ON 07 JUN 2006
L3              STR

     FILE 'REGISTRY' ENTERED AT 14:25:08 ON 07 JUN 2006
L4           50 SEA SSS SAM L3
                D QUE STAT

     FILE 'LREGISTRY' ENTERED AT 14:30:16 ON 07 JUN 2006
L5              STR L3

     FILE 'REGISTRY' ENTERED AT 14:37:11 ON 07 JUN 2006
L6           50 SEA SSS SAM L5

     FILE 'LREGISTRY' ENTERED AT 14:38:33 ON 07 JUN 2006
L7              STR L5

     FILE 'REGISTRY' ENTERED AT 14:38:59 ON 07 JUN 2006
L8            0 SEA SSS SAM L7
                D QUE STAT L6
L9       130587 SEA SSS FUL L5
                SAV TEMP L9 DEV915/A
                D SAV
L10          26 SEA ABB=ON  PLU=ON  L2 AND L9

     FILE 'LREGISTRY' ENTERED AT 14:43:13 ON 07 JUN 2006
L11             STR L5

     FILE 'REGISTRY' ENTERED AT 14:50:32 ON 07 JUN 2006
L12          11 SEA SUB=L9 SSS SAM L11
L13         279 SEA SUB=L9 SSS FUL L11
                SAV L13 DEV915A/A
                D SAV
L14          26 SEA ABB=ON  PLU=ON  L13 AND L2
                D QUE STAT
```

```
     FILE 'LREGISTRY' ENTERED AT 14:56:27 ON 07 JUN 2006
L15             STR L11
                DIS SIA

     FILE 'REGISTRY' ENTERED AT 15:00:49 ON 07 JUN 2006
L16          11 SEA SUB=L9 SSS SAM L15
                D SCAN
                D QUE STAT

     FILE 'LREGISTRY' ENTERED AT 15:12:52 ON 07 JUN 2006
L17             STR L15

     FILE 'REGISTRY' ENTERED AT 15:35:56 ON 07 JUN 2006
L18           0 SEA SUB=L9 SSS SAM L17
L19           0 SEA SUB=L9 SSS FUL L17
                D QUE STAT
                D SCAN L14
L20          25 SEA ABB=ON  PLU=ON  L13 AND 1-10/SI
                D SCAN

     FILE 'LREGISTRY' ENTERED AT 15:42:32 ON 07 JUN 2006
L21             STR

     FILE 'REGISTRY' ENTERED AT 15:44:31 ON 07 JUN 2006
L22           0 SEA SUB=L9 SSS SAM L21
                D QUE STAT
L23           0 SEA SUB=L9 SSS FUL L21

     FILE 'LREGISTRY' ENTERED AT 15:46:09 ON 07 JUN 2006
L24             STR L21

     FILE 'REGISTRY' ENTERED AT 15:47:21 ON 07 JUN 2006
L25           0 SEA SUB=L9 SSS SAM L24
L26       10401 SEA ABB=ON  PLU=ON  L9 AND 1-2/SI
                D QUE STAT L25
L27           2 SEA ABB=ON  PLU=ON  L14 AND 1/P
                D SCAN

     FILE 'LREGISTRY' ENTERED AT 15:52:37 ON 07 JUN 2006
                D QUE STAT L21
                D QUE STAT L17
L28             STR

     FILE 'REGISTRY' ENTERED AT 15:56:08 ON 07 JUN 2006
L29          50 SEA SUB=L9 SSS SAM L28
                D QUE STAT
                D QUE STAT
                D QUE STAT L13
L30           1 SEA SUB=L13 SSS SAM L28
                D SCAN
L31          27 SEA SUB=L13 SSS FUL L28
                D SCAN
                SAV L31 DEV915B/A
                D QUE STAT L13
                D QUE STAT L15

     FILE 'LREGISTRY' ENTERED AT 16:06:49 ON 07 JUN 2006
L32             STR L11

     FILE 'REGISTRY' ENTERED AT 16:16:47 ON 07 JUN 2006
L33           0 SEA SUB=L13 SSS SAM L32
                D QUE STAT

     FILE 'LREGISTRY' ENTERED AT 16:17:55 ON 07 JUN 2006
L34             STR L32
```

```
     FILE 'REGISTRY' ENTERED AT 16:18:35 ON 07 JUN 2006
L35           0 SEA SSS SAM L34
L36           0 SEA SUB=L13 SSS SAM L34
L37          10 SEA ABB=ON  PLU=ON  L13 AND 1/S
                D SCAN
L38           0 SEA ABB=ON  PLU=ON  L2 AND 1/S
                D QUE STAT L31
L39         698 SEA ABB=ON  PLU=ON  L9 AND 1/B
                D QUE STAT L31
L40           5 SEA ABB=ON  PLU=ON  L20 AND 1/SI
                D SCAN

     FILE 'HCAPLUS' ENTERED AT 16:37:09 ON 07 JUN 2006
L41        2192 SEA ABB=ON  PLU=ON  L14
L42       99532 SEA ABB=ON  PLU=ON  L9
L43        2276 SEA ABB=ON  PLU=ON  L13
L44          12 SEA ABB=ON  PLU=ON  L20
L45           1 SEA ABB=ON  PLU=ON  L27
                D SCAN
L46          38 SEA ABB=ON  PLU=ON  L31
L47           9 SEA ABB=ON  PLU=ON  L37
L48         674 SEA ABB=ON  PLU=ON  L14/THU
L49         696 SEA ABB=ON  PLU=ON  L13/THU
L50       13892 SEA ABB=ON  PLU=ON  L9/THU
                D QUE STAT L50
L51           0 SEA ABB=ON  PLU=ON  L20/THU
L52           0 SEA ABB=ON  PLU=ON  L27/THU
L53           1 SEA ABB=ON  PLU=ON  L31/THU
                D SCAN
L54           3 SEA ABB=ON  PLU=ON  L37/THU
                D SCAN
L55     2080101 SEA ABB=ON  PLU=ON  PHARMA?/SC,SX
L56        2276 SEA ABB=ON  PLU=ON  L41 OR (L43 OR L44 OR L45 OR L46
                OR L47)
L57        1348 SEA ABB=ON  PLU=ON  L56 AND L55
L58       74524 SEA ABB=ON  PLU=ON  (VIRAL? OR VIRUS?)(2A)(DISEAS? OR
                ILLNESS? OR INFECTION?)
L59          51 SEA ABB=ON  PLU=ON  L58 AND L57
L60         696 SEA ABB=ON  PLU=ON  L48 OR L49 OR L53 OR L54
L61          40 SEA ABB=ON  PLU=ON  L60 AND L58
L62          40 SEA ABB=ON  PLU=ON  L59 AND L61
L63       30513 SEA ABB=ON  PLU=ON  L42 AND L55
L64        1969 SEA ABB=ON  PLU=ON  L63 AND L58
L65        9659 SEA ABB=ON  PLU=ON  (VIRAL? OR VIRUS?)(2A)TREAT?
L66        9659 SEA ABB=ON  PLU=ON  L65 AND L65
L67       13097 SEA ABB=ON  PLU=ON  L50 AND L55
L68        1214 SEA ABB=ON  PLU=ON  L67 AND (L58 OR L65)
L69         610 SEA ABB=ON  PLU=ON  L68 AND HIV
L70          15 SEA ABB=ON  PLU=ON  L62 AND L65
L71           0 SEA ABB=ON  PLU=ON  L70 NOT L62
L72          40 SEA ABB=ON  PLU=ON  L70 OR L62
L73          26 SEA ABB=ON  PLU=ON  L72 AND 1907-2002/PY,PRY


=>
=> d que stat l19
L5              STR
```



VAR G1=C/N
VAR G2=C/B
NODE ATTRIBUTES:
NSPEC IS RC AT 12
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE
L9 130587 SEA FILE=REGISTRY SSS FUL L5
L17 STR





VAR G1=CH3/16/38
VAR G2=17/19/32
VAR G3=AK/34
NODE ATTRIBUTES:
NSPEC IS RC AT 13
CONNECT IS E1 RC AT 18
DEFAULT MLEVEL IS ATOM

GGCAT IS UNS AT 34
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 40

STEREO ATTRIBUTES: NONE
L19 0 SEA FILE=REGISTRY SUB=L9 SSS FUL L17

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

=> d que stat l22
L5 STR



VAR G1=C/N
VAR G2=C/B
NODE ATTRIBUTES:
NSPEC IS RC AT 12
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE
L9 130587 SEA FILE=REGISTRY SSS FUL L5
L21 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 9

STEREO ATTRIBUTES: NONE
L22 0 SEA FILE=REGISTRY SUB=L9 SSS SAM L21

100.0% PROCESSED 12 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET): ONLINE **COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET): 33 TO 447
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET): 0 TO 0

=> d que stat l73
L2 38 SEA FILE=REGISTRY ABB=ON PLU=ON (10302-79-1/BI OR
105330-91-4/BI OR 105330-94-7/BI OR 105330-96-9/BI OR
106206-74-0/BI OR 108-24-7/BI OR 114522-16-6/BI OR
114522-18-8/BI OR 114522-19-9/BI OR 117399-73-2/BI OR
14215-97-5/BI OR 16352-06-0/BI OR 183016-20-8/BI OR
217090-42-1/BI OR 2353-33-5/BI OR 320-67-2/BI OR
3601-89-6/BI OR 40789-35-3/BI OR 461-58-5/BI OR
57-10-3/BI OR 676607-90-2/BI OR 676607-91-3/BI OR
676607-92-4/BI OR 676607-93-5/BI OR 676607-94-6/BI OR
676607-95-7/BI OR 676607-96-8/BI OR 676607-97-9/BI OR
676607-98-0/BI OR 676607-99-1/BI OR 676608-00-7/BI OR
676608-01-8/BI OR 69304-37-6/BI OR 79-30-1/BI OR
80646-62-4/BI OR 80646-63-5/BI OR 80646-65-7/BI OR
9068-38-6/BI)
L5 STR



VAR G1=C/N
VAR G2=C/B
NODE ATTRIBUTES:
NSPEC IS RC AT 12
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE
L9 130587 SEA FILE=REGISTRY SSS FUL L5
L11 STR



NODE ATTRIBUTES:
NSPEC IS RC AT 12
NSPEC IS RC AT 13
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 14

STEREO ATTRIBUTES: NONE

L13	279	SEA	FILE=REGISTRY	SUB=L9	SSS FUL	L11
L14	26	SEA	FILE=REGISTRY	ABB=ON	PLU=ON	L13 AND L2
L20	25	SEA	FILE=REGISTRY	ABB=ON	PLU=ON	L13 AND 1-10/SI
L27	2	SEA	FILE=REGISTRY	ABB=ON	PLU=ON	L14 AND 1/P
L28		STR				



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE

L31	27	SEA	FILE=REGISTRY	SUB=L13	SSS FUL	L28
L37	10	SEA	FILE=REGISTRY	ABB=ON	PLU=ON	L13 AND 1/S
L41	2192	SEA	FILE=HCAPLUS	ABB=ON	PLU=ON	L14
L43	2276	SEA	FILE=HCAPLUS	ABB=ON	PLU=ON	L13
L44	12	SEA	FILE=HCAPLUS	ABB=ON	PLU=ON	L20
L45	1	SEA	FILE=HCAPLUS	ABB=ON	PLU=ON	L27
L46	38	SEA	FILE=HCAPLUS	ABB=ON	PLU=ON	L31
L47	9	SEA	FILE=HCAPLUS	ABB=ON	PLU=ON	L37
L48	674	SEA	FILE=HCAPLUS	ABB=ON	PLU=ON	L14/THU
L49	696	SEA	FILE=HCAPLUS	ABB=ON	PLU=ON	L13/THU
L53	1	SEA	FILE=HCAPLUS	ABB=ON	PLU=ON	L31/THU
L54	3	SEA	FILE=HCAPLUS	ABB=ON	PLU=ON	L37/THU

```
L55     2080101 SEA FILE=HCAPLUS ABB=ON  PLU=ON  PHARMA?/SC,SX
L56        2276 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L41 OR (L43 OR L44 OR
                L45 OR L46 OR L47)
L57        1348 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L56 AND L55
L58       74524 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (VIRAL? OR VIRUS?)(2A)
                (DISEAS? OR ILLNESS? OR INFECTION?)
L59          51 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L58 AND L57
L60         696 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L48 OR L49 OR L53 OR
                L54
L61          40 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L60 AND L58
L62          40 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L59 AND L61
L65        9659 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (VIRAL? OR VIRUS?)(2A)
                TREAT?
L70          15 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L62 AND L65
L72          40 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L70 OR L62
L73          26 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L72 AND 1907-2002/PY,P
                RY


=> d l73 1-26 ibib abs hitstr hitind

L73  ANSWER 1 OF 26  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2004:565086  HCAPLUS
DOCUMENT NUMBER:          141:123632
TITLE:                    Preparation of 3,5-Disubstituted-[1,2,4]-
                          oxadiazoles and analogs as activators of
                          caspases and inducers of apoptosis
INVENTOR(S):              Cai, Sui Xiong; Zhang, Han-zhong; Kuemmerle,
                          Jared D.; Zhang, Hong; Kemnitzer, William E.
PATENT ASSIGNEE(S):       Cytovia, Inc., USA
SOURCE:                   PCT Int. Appl., 97 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.        DATE
     ---------------      ----   --------    --------------------
     --------
     WO 2004058253         A1    20040715    WO 2003-US40308
                                                                   2003
                                                                   1218
                                                 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,
             CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG,
             ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
             KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
             MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,
             RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT,
             TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW,
             AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY,
             CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
             NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA,
             GN, GQ, GW, ML, MR, NE, SN, TD, TG
     US 2004127521         A1    20040701    US 2003-737865
                                                                   2003
                                                                   1218
                                                 <--
     CA 2509224            AA    20040715    CA 2003-2509224
                                                                   2003
                                                                   1218
                                                 <--
     AU 2003303373         A1    20040722    AU 2003-303373
                                                                   2003
```

1218
<--
EP 1581213 A1 20051005 EP 2003-808469
2003
1218
<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
CN 1756547 A 20060405 CN 2003-80106440
2003
1218
<--
PRIORITY APPLN. INFO.: US 2002-433953P P
2002
1218
<--
WO 2003-US40308 W
2003
1218

OTHER SOURCE(S): MARPAT 141:123632
GI



I



II

AB Title compds. I [R1-3 = H, halo, haloalkyl, aryl, etc.; Q = S, O, amino; A = heterocycle, carbocycle] are prepared For instance, 3-amino-4-chlorobenzamidoxime (preparation given) is reacted with 3-chlorothiophene-2-carbonyl chloride (pyridine, reflux, 50 min) to give II. II and other examples are potent caspase cascade activators and inducers of apoptosis in solid tumor cells, e.g., human breast cancer cell lines T-47D and ZR-75-1.

IT **320-67-2**, 5-Azacytidine
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(combination pharmaceutical; preparation of 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis)

RN 320-67-2 HCAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM A61K031-4245
ICS A61K031-443; A61K031-4525; A61K031-496; A61K031-5377; C07D413-04; C07D413-14
CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): **1**, **63**
IT **Infection**
(**viral**; preparation of 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis)
IT 50-07-7, Mitomycin C 50-91-9, 5-Fluoro-2'-deoxyuridine 51-21-8, 5-Fluorouracil 52-86-8, Haloperidol 55-98-1, Busulfan 57-22-7, Vincristine 59-05-2, Methotrexate 64-86-8, Colchicine 127-07-1, Hydroxyurea 147-94-4, Ara-C 148-82-3, Melphalan 154-42-7, Thioguanine 302-79-4, Retinoic acid 305-03-3, Chlorambucil **320-67-2**, 5-Azacytidine 446-72-0, Genistein 459-86-9, Mitoguazone 865-21-4, Vinblastine 1327-53-3, Arsenic trioxide 3778-73-2, Ifosfamide 4759-48-2, 13-cis-Retinoic acid 5300-03-8, 9-cis-Retinoic acid 5854-93-3, Alanosine 7689-03-4, Camptothecin 10540-29-1, Tamoxifen 11056-06-7, Bleomycin 15663-27-1, Cisplatin 21679-14-1, Fludarabine 23214-92-8, Doxorubicin 33069-62-4, Paclitaxel 33419-42-0, Etoposide 41575-94-4, Carboplatin 56420-45-2, Epirubicin 57576-44-0, Aclarubicin 58337-35-2, Elliptinium 63590-64-7, Terazosin 65271-80-9, Mitoxantrone 65646-68-6, Fenretinide 70052-12-9, α-Difluoromethylornithine 74191-85-8, Doxazosin 74193-17-2, N-4-Carboxyphenylretinamide 75330-75-5, Lovastatin 79902-63-9, Simvastatin 81093-37-0, Pravastatin 83150-76-9, Octreotide 93957-54-1, Fluvastatin 101622-51-9, Olomoucine 106133-20-4, Tamsulosin 112953-11-4, UCN-01 114977-28-5, Docetaxel 118694-43-2, ILX23-7553 123948-87-8, Topotecan 127779-20-8, Saquinavir 133343-34-7, Lactacystin 133407-82-6, MG-132 134523-00-5, Atorvastatin 136470-78-5, Abacavir 145599-86-6, Cerivastatin 146426-40-6, Flavopiridol 150378-17-9, Indinavir 153559-49-0, Bexarotene 155213-67-5, Ritonavir 157752-20-0, CB-64D 159989-64-7, Nelfinavir 161814-49-9, Amprenavir 162011-90-7, Rofecoxib 165307-47-1, CB-184 169590-42-5, Celecoxib 172924-31-1, TAN-1813 174484-41-4, Tipranavir 174722-31-7, Rituxan 175385-62-3, CGP-61755 177932-89-7, DMP-450 179324-69-7, PS-341 180288-69-1, Herceptin 183488-70-2, CEP2563 184475-35-2, ZD1839 186692-46-6, Roscovitine 188968-51-6, EMD121974 192185-68-5, R115777 192725-17-0, ABT-378 193275-84-2, SCH66336 198904-31-3, CGP-73547 220127-57-1, Gleevec 252916-29-3, SU6668 253863-00-2, L-778123 352234-06-1, AG 1776 557795-19-4, SU11248 643757-28-2, SH268
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(combination pharmaceutical; preparation of 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis)

L73 ANSWER 2 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:534300 HCAPLUS
DOCUMENT NUMBER: 141:65094

TITLE: Substituted 1-benzoyl-3-cyano-pyrrolo[1,2-a]quinolines and analogs as activators of caspases and inducers of apoptosis

INVENTOR(S): Cai, Sui Xiong; Drewe, John A.; Jiang, Sungchun; Kasibhatla, Shailaja; Kuemmerle, Jared Daniel; Sirisoma, Nilantha Sudath; Zhang, Han-Zhong

PATENT ASSIGNEE(S): Cytovia, Inc., USA

SOURCE: PCT Int. Appl., 106 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004055163	A2	20040701	WO 2003-US39550	2003 1212
			<--	
WO 2004055163	A3	20040826		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003300883	A1	20040709	AU 2003-300883	2003 1212
			<--	
US 2005014759	A1	20050120	US 2003-733229	2003 1212
			<--	
EP 1578424	A2	20050928	EP 2003-813401	2003 1212
			<--	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			US 2002-432608P P	2002 1212
			<--	
			WO 2003-US39550 W	2003 1212

OTHER SOURCE(S): MARPAT 141:65094

AB The invention discloses substituted 1-benzoyl-3-cyanopyrrolo[1,2-a]quinolines and analogs thereof. Compds. of the invention are activators of caspases and inducers of apoptosis. Therefore, the compds. of the invention can be used to induce cell death in a variety of clin. conditions in which uncontrolled growth and spread of abnormal cells occurs. Compound prepn is described.

IT **320-67-2**, 5-Azacytidine

RL: PAC (Pharmacological activity); **THU (Therapeutic use)**
; BIOL (Biological study); USES (Uses)
(benzoylcyanopyrroloquinolines and analogs as activators of caspases and inducers of apoptosis)
RN 320-67-2 HCAPLUS
CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM C12N
CC 1-6 (**Pharmacology**)
Section cross-reference(s): 28
IT **Infection**
(**viral**; benzoylcyanopyrroloquinolines and analogs as activators of caspases and inducers of apoptosis)
IT 50-07-7, Mitomycin C 50-18-0, Cyclophosphamide 50-91-9, 5-Fluoro-2'-deoxy-uridine 51-21-8, 5-Fluorouracil 52-86-8, Haloperidol 55-98-1, Busulfan 57-22-7, Vincristine 59-05-2, Methotrexate 64-86-8, Colchicine 127-07-1, Hydroxyurea 147-94-4, Ara-C 148-82-3, Melphalan 154-42-7, Thioguanine 302-79-4, Retinoic acid 305-03-3, Chlorambucil **320-67-2**, 5-Azacytidine 446-72-0, Genistein 459-86-9, Mitoguazone 865-21-4, Vinblastine 1327-53-3, Arsenic trioxide 3778-73-2, Ifosfamide 4759-48-2, 13-cis-Retinoic acid 5300-03-8, 9-cis-Retinoic acid 5854-93-3, Alanosine 7689-03-4, Camptothecin 10540-29-1, Tamoxifen 11056-06-7, Bleomycin 15663-27-1, cis-Platin 21679-14-1, Fludarabine 23214-92-8, Doxorubicin 33069-62-4, Paclitaxel 33419-42-0, Etoposide 41575-94-4, Carboplatin 56420-45-2, Epirubicin 57576-44-0, Aclarubicin 58337-35-2, Elliptinium 63590-64-7, Terazosin 65271-80-9, Mitoxantrone 65646-68-6, Fenretinide 70052-12-9, α-Difluoromethylornithine 74191-85-8, Doxazosin 74193-17-2, N-4-Carboxyphenyl retinamide 75330-75-5, Lovastatin 79902-63-9, Simvastatin 81093-37-0, Pravastatin 83150-76-9, Octreotide 93957-54-1, Fluvastatin 95058-81-4, Gemcitabine 101622-51-9, Olomoucine 106133-20-4, Tamsulosin 112953-11-4, UCN-01 114977-28-5, Docetaxel 118694-43-2, ILX23-7553 123948-87-8, Topotecan 127779-20-8, Saquinavir 133343-34-7, Lactacystin 133407-82-6, MG-132 134523-00-5, Atorvastatin 136470-78-5, Abacavir 145599-86-6, Cerivastatin 146426-40-6, Flavopiridol 150378-17-9, Indinavir 153559-49-0, Bexarotene 155213-67-5, Ritonavir 157752-20-0, CB-64D 159989-64-7, Nelfinavir 161814-49-9, Amprenavir 162011-90-7, Rofecoxib 165307-47-1, CB-184 169590-42-5, Celecoxib 172924-31-1, TAN 1813 174484-41-4, Tipranavir 174722-31-7, Rituxan 175385-62-3, CGP-61755 177932-89-7, DMP-450 179324-69-7, PS-341 180288-69-1, Herceptin 181695-72-7, Valdecoxib 183488-70-2, CEP2563 184475-35-2, ZD1839 186692-46-6, Roscovitine 188968-51-6, EMD121974 192185-68-5, R115777 192725-17-0, ABT-378 193275-84-2, SCH66336 198904-31-3, CGP-73547 220127-57-1, Gleevec 252916-29-3, SU6668 253863-00-2, L-778123 352234-06-1, AG 1776 557795-19-4, SU 11248 643757-28-2, SH268 643757-29-3, BAL9611 713076-39-2 713076-45-0 713076-46-1 713076-47-2 713076-54-1

713076-86-9 713076-87-0 713076-98-3 713076-99-4
713077-00-0 713077-01-1
RL: PAC (Pharmacological activity); **THU (Therapeutic use)**
; BIOL (Biological study); USES (Uses)
(benzoylcyanopyrroloquinolines and analogs as activators of caspases and inducers of apoptosis)

L73 ANSWER 3 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:331903 HCAPLUS
DOCUMENT NUMBER: 140:337930
TITLE: Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders in mammal and human
INVENTOR(S): Wahl, Alan F.; Senter, Peter D.; Law, Che-leung; Cerveny, Charles G.
PATENT ASSIGNEE(S): Seattle Genetics, Inc., USA
SOURCE: PCT Int. Appl., 161 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004032828	A2	20040422	WO 2003-US23895	2003 0730
			<--	
WO 2004032828	A3	20060427		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2494104	AA	20040422	CA 2003-2494104	2003 0730
			<--	
AU 2003294210	A1	20040504	AU 2003-294210	2003 0730
			<--	
US 2005180972	A1	20050818	US 2003-632151	2003 0730
			<--	
EP 1575514	A2	20050921	EP 2003-789690	2003 0730
			<--	
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
PRIORITY APPLN. INFO.:			US 2002-400404P P	2002 0731
			<--	

WO 2003-US23895 W
2003
0730

AB The present invention relates to methods and compns. for the treatment of CD20-expressing cancers and immune disorders involving CD20-expressing cells. The present methods comprise administering to a subject an anti CD20 antibody-drug conjugate that has a high potency and/or is capable of internalizing into CD20-expressing cells. The present invention further provides pharmaceutical compns. and kits comprising such conjugates. The present invention yet further provides methods of and compns. relating to combination therapy of cancer and immune disorders involving CD20-expressing cells using the anti-CD20 antibody-drug conjugates of the invention.

IT **320-67-2D**, 5-Azacytidine, conjugates with anti-CD20 antibody
RL: BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders in mammal and human)

RN 320-67-2 HCAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM A61K

CC 15-3 (Immunochemistry)
Section cross-reference(s): **1**, 8, **63**

IT **Infection**
(chronic **viral** hepatitis; anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders in mammal and human)

IT 50-07-7D, Mitomycin C, conjugates with anti-CD20 antibody
50-18-0D, Cyclophosphamide, conjugates with anti-CD20 antibody
50-44-2D, 6-Mercaptopurine, conjugates with anti-CD20 antibody
50-76-0D, Dactinomycin, conjugates with anti-CD20 antibody
50-91-9D, 5-Fluoro-2'-deoxyuridine, conjugates with anti-CD20 antibody 51-21-8D, 5-Fluorouracil, conjugates with anti-CD20 antibody 51-75-2D, Mechlorethamine, conjugates with anti-CD20 antibody 52-24-4D, ThioTEPA, conjugates with anti-CD20 antibody
53-03-2D, Prednisone, conjugates with anti-CD20 antibody
53-79-2D, Puromycin, conjugates with anti-CD20 antibody
54-42-2D, Iododeoxyuridine, conjugates with anti-CD20 antibody
55-98-1D, Busulfan, conjugates with anti-CD20 antibody 57-22-7D, Vincristine, conjugates with anti-CD20 antibody 59-05-2D, Methotrexate, conjugates with anti-CD20 antibody 64-86-8D, Colchicine, conjugates with anti-CD20 antibody 65-46-3D, Cytidine, conjugates with anti-CD20 antibody 70-00-8D, Trifluridine, conjugates with anti-CD20 antibody 127-07-1D, Hydroxyurea, conjugates with anti-CD20 antibody 147-94-4D, Cytarabine, conjugates with anti-CD20 antibody 148-82-3D, Melphalan, conjugates with anti-CD20 antibody 154-42-7D, 6-Thioguanine, conjugates with anti-CD20 antibody 154-93-8D,

Carmustine, conjugates with anti-CD20 antibody 289-95-2D, Pyrimidine, fluorinated derivs and conjugates with anti-CD20 antibody 305-03-3D, Chlorambucil, conjugates with anti-CD20 antibody **320-67-2D**, 5-Azacytidine, conjugates with anti-CD20 antibody 446-86-6D, Azathioprine, conjugates with anti-CD20 antibody 512-64-1D, Echinomycin, conjugates with anti-CD20 antibody 518-28-5, Podophyllotoxin 671-16-9D, Procarbazine, conjugates with anti-CD20 antibody 768-94-5D, Amantadine, conjugates with anti-CD20 antibody 865-21-4D, Vinblastine, conjugates with anti-CD20 antibody 1393-88-0D, Gramicidin D, conjugates with anti-CD20 antibody 1438-30-8D, Netropsin, conjugates with anti-CD20 antibody 1605-68-1D, Taxane, conjugates with anti-CD20 antibody 2998-57-4D, Estramustine, conjugates with anti-CD20 antibody 3778-73-2D, Ifosfamide, conjugates with anti-CD20 antibody 4342-03-4D, Dacarbazine, conjugates with anti-CD20 antibody 4378-14-7D, Buthionine, conjugates with anti-CD20 antibody 4428-95-9D, Foscarnet, conjugates with anti-CD20 antibody 4803-27-4D, Anthramycin, conjugates with anti-CD20 antibody 5536-17-4D, Vidarabine, conjugates with anti-CD20 antibody 5983-09-5D, 2',3'-Dideoxyuridine, conjugates with anti-CD20 antibody 7689-03-4D, Camptothecin, conjugates with anti-CD20 antibody 9015-68-3D, Asparaginase, conjugates with anti-CD20 antibody 10043-66-0D, Iodine-131, conjugates with anti-CD20 antibody, biological studies 10098-91-6D, Yttrium-90, conjugates with anti-CD20 antibody, biological studies 11056-06-7D, Bleomycin, conjugates with anti-CD20 antibody 13010-47-4D, Lomustine, conjugates with anti-CD20 antibody 14265-85-1D, Actinium-225, conjugates with anti-CD20 antibody, biological studies 14616-60-5D, Sulfoximine, conjugates with anti-CD20 antibody 14930-96-2D, Cytochalasin B, conjugates with anti-CD20 antibody 15663-27-1D, Cisplatin, conjugates with anti-CD20 antibody 15750-15-9D, Indium-111, conjugates with anti-CD20 antibody, biological studies 15755-39-2D, Astatine-211, conjugates with anti-CD20 antibody, biological studies 15776-20-2D, Bismuth-213, conjugates with anti-CD20 antibody, biological studies 18378-89-7D, Mithramycin, conjugates with anti-CD20 antibody 18883-66-4D, Streptozotocin, conjugates with anti-CD20 antibody 20830-81-3D, Daunorubicin, conjugates with anti-CD20 antibody 23214-92-8D, Doxorubicin, conjugates with anti-CD20 antibody 29767-20-2D, Teniposide, conjugates with anti-CD20 antibody 30516-87-1D, Zidovudine, conjugates with anti-CD20 antibody 31430-18-9D, Nocodazole, conjugates with anti-CD20 antibody 33069-62-4D, Paclitaxel, conjugates with anti-CD20 antibody 33419-42-0D, Etoposide, conjugates with anti-CD20 antibody 35846-53-8D, Maytansine, conjugates with anti-CD20 antibody 35846-53-8D, Maytansine, maytansinoid derivs. 36791-04-5D, Ribavarin, conjugates with anti-CD20 antibody 36877-68-6D, Nitroimidazole, conjugates with anti-CD20 antibody 39342-51-3D, Colcimide, conjugates with anti-CD20 antibody 41575-94-4D, Carboplatin, conjugates with anti-CD20 antibody 50986-18-0D, Arabinoside, conjugates with anti-CD20 antibody 53123-88-9D, Rapamycin, conjugates with anti-CD20 antibody 53643-48-4D, Vindesine, conjugates with anti-CD20 antibody 58957-92-9D, Idarubicin, conjugates with anti-CD20 antibody 59277-89-3D, Acyclovir, conjugates with anti-CD20 antibody 59865-13-3D, Cyclosporine, conjugates with anti-CD20 antibody 65271-80-9D, Mitoxantrone, conjugates with anti-CD20 antibody 66107-60-6D, Baccatin, derivs. and conjugates with anti-CD20 antibody 69866-21-3D, CC-1065, conjugates with anti-CD20 antibody 71486-22-1D, Vinorelbine, conjugates with anti-CD20 antibody 80790-68-7D, Morpholinodoxorubicin, conjugates with anti-CD20 antibody 82410-32-0D, Gancyclovir, conjugates with anti-CD20 antibody 82855-09-2D, Combretastatin, conjugates with anti-CD20 antibody 86639-52-3D, SN 38, conjugates with anti-CD20 antibody 90996-54-6D, Rhizoxin, conjugates with anti-CD20 antibody

97682-44-5D, Irinotecan, conjugates with anti-CD20 antibody
104987-11-3D, FK 506, conjugates with anti-CD20 antibody
110417-88-4D, Dolastatin 10, conjugates with anti-CD20 antibody
113411-17-9D, DM 1, conjugates with anti-CD20 antibody
113440-58-7D, Calicheamicin, conjugates with anti-CD20 antibody
114977-28-5D, Docetaxel, conjugates with anti-CD20 antibody
121854-21-5D, Lexitropsin, conjugates with anti-CD20 antibody
123948-87-8D, Topotecan, conjugates with anti-CD20 antibody
127943-53-7D, Discodermolide, conjugates with anti-CD20 antibody
128794-94-5D, Mycophenolate mofetil, conjugates with anti-CD20 antibody 129362-95-4D, conjugates with anti-CD20 antibody
159776-69-9D, Cemadotin, conjugates with anti-CD20 antibody
160800-57-7D, Auristatin E, conjugates with anti-CD20 antibody
174545-76-7D, Eleutherobin, conjugates with anti-CD20 antibody
174722-31-7D, Rituximab, conjugates with monomethyl auristatin E
474645-27-7D, conjugates with anti-CD20 antibody 681125-76-8D, Auristatin EB, conjugates with anti-CD20 antibody 681125-78-0D, Auristatin E-FP, conjugates with anti-CD20 antibody
681125-90-6D, Epithilone A, conjugates with anti-CD20 antibody
681125-91-7D, Epithilone B, conjugates with anti-CD20 antibody
RL: BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders in mammal and human)

L73 ANSWER 4 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:290464 HCAPLUS
DOCUMENT NUMBER: 140:297477
TITLE: **Treatment** of **viral diseases** by 1,3,5-triazine nucleoside and nucleotide analogs, and preparation thereof
INVENTOR(S): Daifuku, Richard; Gall, Alexander; Sergueev, Dmitri
PATENT ASSIGNEE(S): Koronis Pharmaceuticals, Incorporated, USA
SOURCE: PCT Int. Appl., 108 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004028454	A2	20040408	WO 2003-US30200	2003 0924
			<--	
WO 2004028454	A3	20041118		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2499036	AA	20040408	CA 2003-2499036	2003 0924
			<--	

AU 2003278904	A1	20040419	AU 2003-278904	2003 0924
			<--	
US 2004127436	A1	20040701	US 2003-670915	2003 0924
			<--	
EP 1545558	A2	20050629	EP 2003-770420	2003 0924
			<--	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006507255	T2	20060302	JP 2004-539890	2003 0924
			<--	
PRIORITY APPLN. INFO.:			US 2002-413337P P	2002 0924
			<--	
			WO 2003-US30200 W	2003 0924

OTHER SOURCE(S): MARPAT 140:297477

GI



I

AB The invention discloses a genus of nucleoside or nucleotide analogs I [Y=C, CH, N; Z=C,CH,B; R1=H, acyl, NHNH2, etc; R2=absent, H, acyl, etc; R3=H, acyl, (un)substituted alkyl, etc.; R4, R4a=H, halo, OMe, OH; R5, R6=H, OR14 (R14= H, (un)substituted alkyl, etc.;) R7,R8=absent, H, acyl, etc.] for use as antiviral agents. In a first aspect, there is provided a compound according to Formula I as shown. In another aspect, the nucleoside and nucleotide analogs according to Formula I are used to **treat** a **viral disease** by administrating a therapeutically effective amount of a compound of Formula I to patient with a **viral disease** which is caused by an RNA virus, a DNA virus, a retrovirus, or HIV. Preparation of selected analogs is described.

IT **114522-16-6P**

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(**treatment** of **viral diseases**

1,3,5-triazine nucleoside and nucleotide analogs, and preparation thereof)

RN 114522-16-6 HCAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-3,6-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **676607-98-0P**

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)

(**treatment** of **viral diseases**

1,3,5-triazine nucleoside and nucleotide analogs, and preparation thereof)

RN 676607-98-0 HCAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-[2-deoxy-5-O-(1-oxohexadecyl)-β-D-erythro-pentofuranosyl]-5,6-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **2353-33-5P**, 2'-Deoxy-5-azacytidine

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(**treatment** of **viral diseases**

1,3,5-triazine nucleoside and nucleotide analogs, and preparation thereof)

RN 2353-33-5 HCAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **320-67-2**, 5-Azacytidine
RL: PAC (Pharmacological activity); RCT (Reactant); **THU (Therapeutic use)**; BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(treatment of viral diseases
1,3,5-triazine nucleoside and nucleotide analogs, and preparation thereof)
RN 320-67-2 HCAPLUS
CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **80646-65-7 105330-91-4 106206-74-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(treatment of viral diseases
1,3,5-triazine nucleoside and nucleotide analogs, and preparation thereof)
RN 80646-65-7 HCAPLUS
CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 105330-91-4 HCAPLUS
CN 1,3,5-Triazin-2(1H)-one, 4-amino-6-methyl-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 106206-74-0 HCAPLUS
CN 1,3,5-Triazin-2(1H)-one, 4-amino-6-phenyl-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **10302-79-1P 40789-35-3P 105330-94-7P**
114522-18-8P 117399-73-2P 676607-90-2P
676607-91-3P 676607-92-4P 676607-93-5P
676607-95-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(treatment of viral diseases
1,3,5-triazine nucleoside and nucleotide analogs, and preparation thereof)
RN 10302-79-1 HCAPLUS
CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)-β-D-erythro-pentofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 40789-35-3 HCAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)-α-D-erythro-pentofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 105330-94-7 HCAPLUS
CN 1,3,5-Triazin-2(1H)-one, 4-amino-6-methyl-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 114522-18-8 HCAPLUS
CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)-β-D-erythro-pentofuranosyl]-3,6-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 117399-73-2 HCAPLUS
CN Propanamide, N-[5-[2-deoxy-3,5-O-[1,1,3,3-tetrakis(1-methylethyl)-1,3-disiloxanediyl]-β-D-erythro-pentofuranosyl]hexahydro-4-oxo-1,3,5-triazin-2-yl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676607-90-2 HCAPLUS
CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-[3,5-O-[1,1,3,3-tetrakis(1-methylethyl)-1,3-disiloxanediyl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676607-91-3 HCAPLUS
CN 1,3,5-Triazin-2(1H)-one, 4-amino-5,6-dihydro-1-[3,5-O-[1,1,3,3-tetrakis(1-methylethyl)-1,3-disiloxanediyl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676607-92-4 HCAPLUS
CN Propanamide, 2-methyl-N-[1,4,5,6-tetrahydro-4-oxo-5-[3,5-O-[1,1,3,3-tetrakis(1-methylethyl)-1,3-disiloxanediyl]-β-D-ribofuranosyl]-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676607-93-5 HCAPLUS
CN Propanamide, 2-methyl-N-[1,4,5,6-tetrahydro-1-methyl-4-oxo-5-[3,5-O-[1,1,3,3-tetrakis(1-methylethyl)-1,3-disiloxanediyl]-β-D-ribofuranosyl]-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676607-95-7 HCAPLUS
CN Propanamide, N-[5-[2-deoxy-3,5-O-[1,1,3,3-tetrakis(1-methylethyl)-1,3-disiloxanediyl]-β-D-erythro-pentofuranosyl]-1,4,5,6-tetrahydro-1-methyl-4-oxo-1,3,5-triazin-2-yl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **80646-62-4P 80646-63-5P 105330-96-9P**
114522-19-9P 183016-20-8P 676607-94-6P
676607-96-8P 676607-97-9P 676607-99-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(**treatment of viral diseases**
1,3,5-triazine nucleoside and nucleotide analogs, and preparation thereof)

RN 80646-62-4 HCAPLUS
CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)-α-D-erythro-pentofuranosyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 80646-63-5 HCAPLUS
CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)-β-D-erythro-pentofuranosyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 105330-96-9 HCAPLUS
CN 1,3,5-Triazin-2(1H)-one, 4-amino-6-phenyl-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 114522-19-9 HCAPLUS
CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)-α-D-erythro-pentofuranosyl]-3,6-dihydro-

(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183016-20-8 HCAPLUS
CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-[2,3-O-(ethoxymethylene)-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676607-94-6 HCAPLUS
CN 1,3,5-Triazin-2(1H)-one, 4-amino-5,6-dihydro-5-methyl-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676607-96-8 HCAPLUS
CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-5,6-dihydro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676607-97-9 HCAPLUS
CN L-Alanine, N-[P-(4-bromophenyl)-2'-deoxy-5'-cytidylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676607-99-1 HCAPLUS
CN L-Alanine, N-[P-(4-bromophenyl)-5'-cytidylyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM A61K
CC 1-5 (**Pharmacology**)
Section cross-reference(s): 28, 33
IT Nucleotides, biological studies
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(analogs; **treatment** of **viral diseases** 1,3,5-triazine nucleoside and nucleotide analogs, and preparation thereof)
IT Drug resistance
(antiviral; **treatment** of **viral diseases** 1,3,5-triazine nucleoside and nucleotide analogs, and preparation thereof)
IT Drug delivery systems

(aqueous; **treatment** of **viral diseases** 1,3,5-triazine nucleoside and nucleotide analogs, and preparation thereof)

IT Polyelectrolytes
(cationic; **treatment** of **viral diseases** 1,3,5-triazine nucleoside and nucleotide analogs, and preparation thereof)

IT Polyamines
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(dendrimers; **treatment** of **viral diseases** 1,3,5-triazine nucleoside and nucleotide analogs, and preparation thereof)

IT Drug delivery systems
(enteric; **treatment** of **viral diseases** 1,3,5-triazine nucleoside and nucleotide analogs, and preparation thereof)

IT Drug delivery systems
(oral, osmotic device; **treatment** of **viral diseases** 1,3,5-triazine nucleoside and nucleotide analogs, and preparation thereof)

IT Dendritic polymers
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(polyamines; **treatment** of **viral diseases** 1,3,5-triazine nucleoside and nucleotide analogs, and preparation thereof)

IT Cations
(polyvalent; **treatment** of **viral diseases** 1,3,5-triazine nucleoside and nucleotide analogs, and preparation thereof)

IT Drug delivery systems
(prodrugs; **treatment** of **viral diseases** 1,3,5-triazine nucleoside and nucleotide analogs, and preparation thereof)

IT Antiviral agents
(resistance to; **treatment** of **viral diseases** 1,3,5-triazine nucleoside and nucleotide analogs, and preparation thereof)

IT AIDS (**disease**)
Anti-AIDS agents
Antiviral agents
DNA **viruses**
Drug delivery systems
Flaviviridae
Hepatitis B **virus**
Hepatitis C **virus**
Human
Human immunodeficiency **virus** 1
Mutagens
Paramyxoviridae
RNA **viruses**
Retroviridae
Vaccinia **virus**
Variola **virus**
(**treatment** of **viral diseases** 1,3,5-triazine nucleoside and nucleotide analogs, and preparation thereof)

IT Nucleoside analogs
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**treatment** of **viral diseases** 1,3,5-triazine nucleoside and nucleotide analogs, and preparation thereof)

IT **Infection**
(**viral**; **treatment** of **viral diseases** 1,3,5-triazine nucleoside and nucleotide

analogs, and preparation thereof)

IT 9068-38-6
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HIV; **treatment** of **viral diseases**
1,3,5-triazine nucleoside and nucleotide analogs, and preparation thereof)

IT **114522-16-6P**
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(**treatment** of **viral diseases**
1,3,5-triazine nucleoside and nucleotide analogs, and preparation thereof)

IT **676607-98-0P**
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(**treatment** of **viral diseases**
1,3,5-triazine nucleoside and nucleotide analogs, and preparation thereof)

IT **2353-33-5P**, 2'-Deoxy-5-azacytidine
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(**treatment** of **viral diseases**
1,3,5-triazine nucleoside and nucleotide analogs, and preparation thereof)

IT **320-67-2**, 5-Azacytidine
RL: PAC (Pharmacological activity); RCT (Reactant); **THU (Therapeutic use)**; BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(**treatment** of **viral diseases**
1,3,5-triazine nucleoside and nucleotide analogs, and preparation thereof)

IT 57-10-3, Palmitic acid, reactions 79-30-1, Isobutyryl chloride 108-24-7, Acetic anhydride 461-58-5 3601-89-6 69304-37-6 **80646-65-7 105330-91-4 106206-74-0** 217090-42-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(**treatment** of **viral diseases**
1,3,5-triazine nucleoside and nucleotide analogs, and preparation thereof)

IT **10302-79-1P** 16352-06-0P **40789-35-3P** **105330-94-7P** **114522-18-8P** **117399-73-2P** **676607-90-2P** **676607-91-3P** **676607-92-4P** **676607-93-5P** **676607-95-7P** 676608-00-7P 676608-01-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(**treatment** of **viral diseases**
1,3,5-triazine nucleoside and nucleotide analogs, and preparation thereof)

IT 14215-97-5P **80646-62-4P** **80646-63-5P** **105330-96-9P** **114522-19-9P** **183016-20-8P** **676607-94-6P** **676607-96-8P** **676607-97-9P** **676607-99-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(**treatment** of **viral diseases**
1,3,5-triazine nucleoside and nucleotide analogs, and preparation thereof)

L73 ANSWER 5 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:182244 HCAPLUS
DOCUMENT NUMBER: 140:223261

TITLE: Polymeric delivery systems
INVENTOR(S): Griffiths, Gary L.; Goldenberg, David M.; Hansen, Hans J.
PATENT ASSIGNEE(S): Immunomedics, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 24 pp., Cont.-in-part of U.S. Ser. No. 209,592.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004043030	A1	20040304	US 2003-456580	2003 0609
US 2003026764	A1	20030206	US 2002-209592	2002 0731
CA 2455856	AA	20030213	CA 2002-2455856	2002 0731
EP 1411987	A2	20040428	EP 2002-749088	2002 0731
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005501052	T2	20050113	JP 2003-516572	2002 0731

PRIORITY APPLN. INFO.:		
US 2001-308605P	P	2001 0731
US 2002-209592	A2	2002 0731
WO 2002-GB3494	W	2002 0731

AB The present invention relates to a method of targeting an agent towards a targeting site in a tissue comprising administering a multi-specific antibody or antibody fragment comprising a targeting arm and a capture arm that binds to a polymer conjugate, and administering a polymer conjugate to the tissue. The present invention also relates to a kit for targeting a target site within a comprising a multi-specific antibody or antibody fragment comprising a targeting arm and a capture arm that binds to a polymer conjugate, and a polymer conjugate.

IT **320-67-2D**, Azacytidine, antibody-polymer conjugates
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(polymeric delivery systems)
RN 320-67-2 HCAPLUS
CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM G01N033-574
ICS A61K039-395
INCL 424178100; 424155100; 435007230
CC 63-5 (**Pharmaceuticals**)
Section cross-reference(s): 8, 15
IT **Infection**
(**viral**; polymeric delivery systems)
IT 50-02-2D, Dexamethasone, antibody-polymer conjugates 50-18-0D, Cyclophosphamide, antibody-polymer conjugates 50-35-1D, Thalidomide, antibody-polymer conjugates 50-44-2D, Mercaptopurine, antibody-polymer conjugates 50-76-0D, Dactinomycin, antibody-polymer conjugates 50-91-9D, Floxuridine, antibody-polymer conjugates 51-21-8D, Fluracil, antibody-polymer conjugates 51-75-2D, Mechlorethamine, antibody-polymer conjugates 52-24-4D, Thiotepa, antibody-polymer conjugates 53-03-2D, Prednisone, antibody-polymer conjugates 53-19-0D, Mitotane, antibody-polymer conjugates 55-98-1D, Busulfan, antibody-polymer conjugates 56-53-1D, Diethylstilbestrol, antibody-polymer conjugates 57-13-6D, Urea, derivs., antibody-polymer conjugates 57-22-7D, Vincristine, antibody-polymer conjugates 57-63-6D, Ethinyl estradiol, antibody-polymer conjugates 57-85-2D, Testosterone propionate, antibody-polymer conjugates 58-05-9D, Leucovorin, antibody-polymer conjugates 59-05-2D, Methotrexate, antibody-polymer conjugates 59-30-3D, Folic acid, analogs, antibody-polymer conjugates 60-34-4D, Methylhydrazine, derivs., antibody-polymer conjugates 66-75-1D, Uracil mustard, antibody-polymer conjugates 71-58-9D, Medroprogesterone acetate, antibody-polymer conjugates 76-43-7D, Fluoxymesterone, antibody-polymer conjugates 120-73-0D, Purine, analogs, antibody-polymer conjugates 127-07-1D, Hydroxyurea, antibody-polymer conjugates 147-94-4D, Cytarabine, antibody-polymer conjugates 148-82-3D, Melphalan, antibody-polymer conjugates 151-56-4D, Ethylenimine, derivs., antibody-polymer conjugates 154-42-7D, Thioguanine, antibody-polymer conjugates 154-93-8D, Carmustine, antibody-polymer conjugates 289-95-2D, Pyrimidine, analogs, antibody-polymer conjugates 305-03-3D, Chlorambucil, antibody-polymer conjugates **320-67-2D**, Azacytidine, antibody-polymer conjugates 595-33-5D, Megestrol acetate, antibody-polymer conjugates 630-56-8D, Hydroxyprogesterone caproate, antibody-polymer conjugates 671-16-9D, Procarbazine, antibody-polymer conjugates 865-21-4D, Vinblastine, antibody-polymer conjugates 1404-00-8D, Mitomycin, antibody-polymer conjugates 2169-64-4D, Azaribine, antibody-polymer conjugates 2998-57-4D, Estramustine, antibody-polymer conjugates 3778-73-2D, Ifosfamide, antibody-polymer conjugates 4291-63-8D, Cladribine, antibody-polymer conjugates 4342-03-4D, Dacarbazine, antibody-polymer conjugates 4346-18-3D, Phenyl butyrate, antibody-polymer conjugates 7440-06-4D, Platinum, complexes, antibody-polymer conjugates 7440-42-8D, Boron, compds.

9015-68-3D, L-Asparaginase, antibody-polymer conjugates
10540-29-1D, Tamoxifen, antibody-polymer conjugates 11056-06-7D, Bleomycin, antibody-polymer conjugates 13010-20-3D, Nitrosourea, derivs., antibody-polymer conjugates 13010-47-4D, Lomustine, antibody-polymer conjugates 13311-84-7D, Flutamide, antibody-polymer conjugates 13909-09-6D, Semustine, antibody-polymer conjugates 14459-29-1D, Hematoporphyrin, derivs., antibody-polymer conjugates 15056-34-5D, Triazene, derivs., antibody-polymer conjugates 15663-27-1D, Cisplatin, antibody-polymer conjugates 18378-89-7D, Mithramycin, antibody-polymer conjugates 18883-66-4D, Streptozocin, antibody-polymer conjugates 20830-81-3D, Daunorubicin, antibody-polymer conjugates 21679-14-1D, Fludarabine, antibody-polymer conjugates 23214-92-8D, Doxorubicin, antibody-polymer conjugates 29767-20-2D, Teniposide, antibody-polymer conjugates 33069-62-4D, Paclitaxel, antibody-polymer conjugates 33419-42-0D, Etoposide, antibody-polymer conjugates 41575-94-4D, Carboplatin, antibody-polymer conjugates 53910-25-1D, Pentostatin, antibody-polymer conjugates 58957-92-9D, Idarubicin, antibody-polymer conjugates 65271-80-9D, Mitoxantrone, antibody-polymer conjugates 71486-22-1D, Vinorelbine, antibody-polymer conjugates 83314-01-6D, Bryostatin-1, antibody-polymer conjugates 84370-49-0D, sulfonated derivs., antibody-polymer conjugates 95058-81-4D, Gemcitabine, antibody-polymer conjugates 97682-44-5D, Irinotecan, antibody-polymer conjugates 113471-15-1D, Tin etiopurpurin, antibody-polymer conjugates 114977-28-5D, Docetaxel, antibody-polymer conjugates 120511-73-1D, Anastrozole, antibody-polymer conjugates 123948-87-8D, Topotecan, antibody-polymer conjugates 129497-78-5D, BPD-MA, antibody-polymer conjugates 169590-42-5D, Celebrex, antibody-polymer conjugates 246252-04-0D, Lutetium texaphyrin, antibody-polymer conjugates
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(polymeric delivery systems)

L73 ANSWER 6 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:113472 HCAPLUS
DOCUMENT NUMBER: 140:175116
TITLE: Method for treating T-lineage leukemias and lymphomas using a CD7-specific monoclonal antibody (TXU-7) linked to the pokeweed antiviral protein (PAP)
INVENTOR(S): Uckun, Fatih M.
PATENT ASSIGNEE(S): Regents of the University of Minnesota, USA
SOURCE: U.S., 29 pp., Cont.-in-part of U.S. Ser. No. 14,028.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6689362	B1	20040210	US 1999-453641	1999 1203 <--
US 6372217	B1	20020416	US 1998-14028	1998 0127 <--

PRIORITY APPLN. INFO.: US 1997-48364P P 1997 0603
<--
US 1998-14028 A2 1998 0127
<--

AB Acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) are common leukemias in both children and adults. Current treatment strategies are inadequate and often result in patient toxicity and relapse. Accordingly, the need exists for a T-cell-specific immunotoxin with sufficient stability and efficacy to eliminate cell populations associated with various T-cell malignancies. The invention addresses this concern by providing a biotherapeutic agent (e.g., an immunoconjugate or immunotoxin) comprising a monoclonal antibody (MoAb TXU-7; specific to mammalian T-cell/myeloid antigen CD7) linked to the pokeweed antiviral protein (PAP). The CD7 antigen is expressed on human T-lineage lymphoid cells and leukemic progenitor cells in T-lineage lymphoid malignancies. PAP is a member of the hemitoxin group of toxins and inactivates ribosomes by the removal of a single adenosine from the conserved loop sequence found near the 3' terminus of all larger RNAs. This specific depurination abrogates the ability of elongation factors to interact with ribosomes and results in irreversible shut-down of protein synthesis. The PAP toxin was linked to the TXU-7 Mab to produce a TXU-7-PAP immunoconjugate. This immunotoxin is stable in vivo and effective in killing and eliminating CD7-expressing T-lineage leukemic cells. Antiviral activity (against HIV-1) of the conjugate is also included.

IT **320-67-2**, 5-Azacytidine
RL: PAC (Pharmacological activity); **THU (Therapeutic use)** ; BIOL (Biological study); USES (Uses)
(CD7-specific monoclonal antibody linked to pokeweed antiviral protein for treating T-lineage leukemias and lymphomas, and use with other agents)

RN 320-67-2 HCAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM A61K039-395

INCL 424155100; 424154100; 530388750; 530388800

CC 1-6 (**Pharmacology**)
Section cross-reference(s): 15, **63**

IT **Infection**
(**viral**; CD7-specific monoclonal antibody linked to pokeweed antiviral protein for treating T-lineage leukemias and lymphomas, and use with other agents)

IT 50-18-0, Cyclophosphamide 50-44-2, Mercaptopurine 51-21-8, 5-Fluorouracil 59-05-2, Methotrexate 147-94-4, Cytarabine 154-42-7, Thioguanine **320-67-2**, 5-Azacytidine 2627-62-5 52128-35-5, Trimetrexate

RL: PAC (Pharmacological activity); **THU (Therapeutic use)** ; BIOL (Biological study); USES (Uses)
(CD7-specific monoclonal antibody linked to pokeweed antiviral protein for treating T-lineage leukemias and lymphomas, and use with other agents)

REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L73 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:20448 HCAPLUS
DOCUMENT NUMBER: 140:87676
TITLE: Derivatives of gambogic acid and analogs as activators of caspases and inducers of apoptosis
INVENTOR(S): Tseng, Ben; Sirisoma, Nilantha Sudath; Cai, Sui Xiong; Zhang, Han-Zhong; Kasibhatla, Shailaja; Ollis, Kristin P.; Drewe, John A.
PATENT ASSIGNEE(S): Cytovia, Inc., USA
SOURCE: PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004002428	A2	20040108	WO 2003-US20668	2003 0701 <--
WO 2004002428	A3	20050616		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2491698	AA	20040108	CA 2003-2491698	2003 0701 <--
AU 2003267977	A1	20040119	AU 2003-267977	2003 0701 <--
US 2004082066	A1	20040429	US 2003-609670	2003 0701 <--
EP 1562598	A2	20050817	EP 2003-748924	2003 0701 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1738620	A	20060222	CN 2003-815628	

					2003 0701
			<--		
JP 2006507227	T2	20060302	JP 2004-518157		2003 0701
			<--		
PRIORITY APPLN. INFO.:			US 2002-392358P	P	2002 0701
			<--		
			US 2002-413649P	P	2002 0926
			<--		
			WO 2003-US20668	W	2003 0701

OTHER SOURCE(S): MARPAT 140:87676

AB The invention is directed to derivs. of gambogic acid and analogs thereof. Exemplary gambogic acid derivs. of the present invention include, among others, derivs. substituted in the C10 and C28 positions of gambogic acid. The present invention also relates to the discovery that certain preferred compds. of the invention are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clin. conditions in which uncontrolled growth and spread of abnormal cells occurs.

IT **320-67-2**, 5-Azacytidine
RL: PAC (Pharmacological activity); **THU (Therapeutic use)** ; BIOL (Biological study); USES (Uses)
(derivs. of gambogic acid and analogs as activators of caspases and inducers of apoptosis)

RN 320-67-2 HCAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM A61K

CC 1-6 (**Pharmacology**)
Section cross-reference(s): 8, 14, **63**

IT **Infection**
(**viral**; derivs. of gambogic acid and analogs as activators of caspases and inducers of apoptosis)

IT 50-07-7, Mitomycin C 50-18-0, Cyclophosphamide 50-91-9, 5-Fluoro-2'-deoxyuridine 51-21-8, 5-Fluorouracil 52-86-8, Haloperidol 55-98-1, Busulfan 57-22-7, Vincristine 59-05-2, Methotrexate 64-86-8, Colchicine 127-07-1, Hydroxyurea 147-94-4, Ara-C 148-82-3, Melphalan 154-42-7, Thioguanine 302-79-4, Retinoic acid 305-03-3, Chlorambucil **320-67-2** , 5-Azacytidine 446-72-0, Genistein 459-86-9, Mitoguazone 865-21-4, Vinblastine 1327-53-3, Arsenic trioxide 3778-73-2, Ifosfamide 4759-48-2, 13-cis-Retinoic acid 5300-03-8,

9-cis-Retinoic acid 5854-95-5, Alanosine 7689-03-4, Camptothecin 10540-29-1, Tamoxifen 11056-06-7, Bleomycin 15663-27-1, Cisplatin 21679-14-1, Fludarabine 23214-92-8, Doxorubicin 33069-62-4, Paclitaxel 33419-42-0, Etoposide 41575-94-4, Carboplatin 56420-45-2, Epirubicin 57576-44-0, Aclarubicin 58337-35-2, Elliptinium 63590-64-7, Terazosin 65271-80-9, Mitoxantrone 65646-68-6, Fenretinide 70052-12-9, α-Difluoromethylornithine 74191-85-8, Doxazosin 74193-17-2, N-4-Carboxyphenylretinamide 75330-75-5, Lovastatin 79902-63-9, Simvastatin 81093-37-0, Pravastatin 83150-76-9, Octreotide 93957-54-1, Fluvastatin 95058-81-4, Gemcitabine 101622-51-9, Olomoucine 106133-20-4, Tamsulosin 112953-11-4, UCN-01 114977-28-5, Docetaxel 118694-43-2, ILX23-7553 123948-87-8, Topotecan 127779-20-8, Saquinavir 133343-34-7, Lactacystin 133407-82-6, MG-132 134523-00-5, Atorvastatin 136470-78-5, Abacavir 145599-86-6, Cerivastatin 146426-40-6, Flavopiridol 150378-17-9, Indinavir 153559-49-0, Bexarotene 155213-67-5, Ritonavir 157752-20-0, CB-64D 159989-64-7, Nelfinavir 161814-49-9, Amprenavir 162011-90-7, Rofecoxib 165307-47-1, CB-184 169590-42-5, Celecoxib 172924-31-1, TAN 1813 174484-41-4, Tipranavir 174722-31-7, Rituxan 175385-62-3, CGP-61755 177932-89-7, DMP-450 179324-69-7, PS-341 180288-69-1, Herceptin 181695-72-7, Valdecoxib 183488-70-2, CEP2563 184475-35-2, ZD1839 188968-51-6, EMD121974 192185-68-5, R 115777 192725-17-0, ABT-378 193275-84-2, SCH66336 198904-31-3, CGP-73547 220127-57-1, Gleevec 252916-29-3, SU6668 253863-00-2, L-778123 286934-78-9 286934-79-0 286934-81-4 286934-82-5 286934-83-6 286934-85-8 286934-92-7 286935-00-0 286935-55-5 286935-67-9 286935-68-0 286935-69-1 286935-70-4 286935-71-5 286935-72-6 352234-06-1, AG 1776 557795-19-4, SU11248 642408-99-9 642409-00-5 642409-01-6 642409-16-3 642409-17-4 642409-18-5 642409-19-6 642409-20-9 642409-21-0 642409-22-1 642409-23-2 642409-24-3 642409-26-5 642409-39-0 642409-40-3 643727-34-8 643757-28-2, SH 268 643757-29-3, BAL 9611
RL: PAC (Pharmacological activity); **THU (Therapeutic use)** ; BIOL (Biological study); USES (Uses)
(derivs. of gambogic acid and analogs as activators of caspases and inducers of apoptosis)

L73 ANSWER 8 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:656581 HCAPLUS
DOCUMENT NUMBER: 139:197370
TITLE: Preparation of aryl ureas containing pyridine, quinoline and isoquinoline N-oxide functionality as kinase inhibitors
INVENTOR(S): Dumas, Jacques; Scott, William J.; Riedl, Bernd
PATENT ASSIGNEE(S): Bayer Corporation, USA
SOURCE: PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003068229	A1	20030821	WO 2003-US4110	2003 0211

<--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI,

GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,
KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,
MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD,
SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL,
PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG

AU 2003209119	A1	20030904	AU 2003-209119	2003 0211 <--
US 2003216396	A1	20031120	US 2003-361850	2003 0211 <--
PRIORITY APPLN. INFO.:			US 2002-354935P P	2002 0211 <--
			WO 2003-US4110 W	2003 0211

OTHER SOURCE(S): MARPAT 139:197370
GI



I

AB The title ureas containing a pyridine, quinoline, or isoquinoline functionality which is oxidized at the nitrogen heteroatom MLBNHCONHA [A = (un)substituted Ph, naphthyl, 5-6 membered monocyclic heteroaryl, 8-10 membered bicyclic heteroaryl; B = (un)substituted phenylene, naphthylene, 5-6 membered monocyclic heteroarylene, 8-10 membered bicyclic heteroarylene; L = (CH2)mO(CH2)l, (CH2)m(CH2)l, (CH2)mCO(CH2)l, etc.; m, l = 0-4; M = (un)substituted pyridine-1-oxide, quinoline-1-oxide, isoquinoline-1-oxide; with the provisos] which are useful in the treatment of (i) raf mediated diseases, for example, cancer, (ii) p38 mediated diseases such as inflammation and osteoporosis, and (iii) VEGF mediated diseases such as angiogenesis disorders, were claimed. Preparation of two ureas such as I [R = H, Me] which are not compds. of the invention, and have been distinguished from the compds. of the invention by a proviso, was described. Pharmaceutical composition comprising the title ureas was claimed.

IT **320-67-2**, 5-Azacytidine
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(preparation of aryl ureas containing pyridine, quinoline and isoquinoline N-oxide functionality for use in combination with other anti-proliferative agent)

RN 320-67-2 HCAPLUS
CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-β-D-ribofuranosyl- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.



IC ICM A61K031-44
ICS A61K031-47; C07D213-89; C07D215-60; C07D217-08; A61P035-00; A61P029-00
CC 27-16 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): **1**, **63**
IT Borrelia burgdorferi
Cytomegalovirus
Human immunodeficiency **virus**
Influenza **virus**
Theiler's murine encephalomyelitis **virus**
Treponema pallidum
(**treatment** of **infections** from; preparation of aryl ureas containing pyridine, quinoline and isoquinoline N-oxide functionality as kinase inhibitors)
IT 50-07-7, Mitomycin C 50-18-0, Cyclophosphamide 50-24-8, Prednisolone 50-44-2, 6-Mercaptopurine 50-76-0, Dactinomycin 50-91-9, 5-Fluorodeoxyuridine 51-21-8, 5-Fluorouracil 51-75-2, Mechlorethamine 52-24-4, Thiotepa 53-03-2, Prednisone 53-19-0, Mitotane 55-98-1, Busulfan 56-53-1, Diethylstilbestrol 57-22-7, Vincristine 57-63-6, Ethinyl estradiol 57-85-2, Testosterone propionate 58-05-9, Leucovorin 58-96-8, Uridine 59-05-2, Methotrexate 71-58-9, Medroxyprogesterone acetate 76-43-7, Fluoxymesterone 125-84-8, Aminoglutethimide 127-07-1, Hydroxyurea 134-46-3, 5-Fluorodeoxyuridine monophosphate 147-94-4, Cytarabine 148-82-3, Melphalan 154-42-7, Thioguanine 154-93-8, Carmustine 305-03-3, Chlorambucil **320-67-2**, 5-Azacytidine 446-86-6, Azathioprine 595-33-5, Megestrol acetate 630-56-8, Hydroxyprogesterone caproate 645-05-6, Hexamethylmelamine 671-16-9, Procarbazine 865-21-4, Vinblastine 3778-73-2, Ifosfamide 4291-63-8, Cladribine 4342-03-4, Dacarbazine 5536-17-4, Ara A 9015-68-3, Asparaginase 10540-29-1, Tamoxifen 11056-06-7, Bleomycin 13010-47-4, Lomustine 13311-84-7, Flutamide 13909-09-6, Semustine 15663-27-1, Cisplatin 18378-89-7, Plicamycin 18883-66-4, Streptozocin 19767-45-4, Mesna 20830-81-3, Daunorubicin 23214-92-8, Doxorubicin 29767-20-2, Teniposide 33069-62-4, Paclitaxel 33419-42-0, Etoposide 41575-94-4, Carboplatin 51321-79-0 53643-48-4, Vindesine 53910-25-1, Pentostatin 56420-45-2, Epirubicin 58957-92-9, Idarubicin 61825-94-3, Oxaliplatin 65271-80-9, Mitoxantrone 71486-22-1, Vinorelbine 75607-67-9, Fludarabine phosphate 84449-90-1 95058-81-4, 2',2'-Difluorodeoxycytidine 97682-44-5, Irinotecan 114977-28-5, Taxotere 123948-87-8, Topotecan 180288-69-1, Herceptin
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(preparation of aryl ureas containing pyridine, quinoline and isoquinoline N-oxide functionality for use in combination with other anti-proliferative agent)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE

IN THE RE FORMAT

L73 ANSWER 9 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:656575 HCAPLUS
DOCUMENT NUMBER: 139:197476
TITLE: Preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity
INVENTOR(S): Dumas, Jacques; Scott, William J.; Elting, James; Hatoum-Makdad, Holia
PATENT ASSIGNEE(S): Bayer Corporation, USA
SOURCE: PCT Int. Appl., 142 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003068223	A1	20030821	WO 2003-US4102	2003 0211
			<--	
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2003210969	A1	20030904	AU 2003-210969	2003 0211
			<--	
US 2004023961	A1	20040205	US 2003-361844	2003 0211
			<--	
PRIORITY APPLN. INFO.:			US 2002-354948P P	2002 0211
			<--	
			WO 2003-US4102 W	2003 0211

GI



I

AB 283 Of the title ureas useful for treating diseases mediated by raf kinase and diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes, were claimed. Synthesis of 6 ureas such as I was described. Thus, reacting 3-(tert-butyl)-1-(4-methylphenyl)pyrazole-5-ylamine with 4-(2-morpholin-4-ylethoxy)naphthylamine (prepns. given) and CDI in CH2Cl2 afforded 80% I which showed IC50 of < 1 μM in in vitro raf kinase and in in vitro Flk-1 ELISA assay.

IT **320-67-2**, 5-Azacytidine
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(anti-proliferative agent; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity for treating hyper-proliferative disorder in combination with addnl. anti-proliferative agent)

RN 320-67-2 HCAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM A61K031-415
ICS A61K031-5355; A61K031-4439; A61K031-4178; A61P035-00; A61P017-06; A61P019-02; A61P027-02; A61P031-06; A61P031-18; A61P031-04

CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): **1, 63**

IT Borrelia burgdorferi
Cytomegalovirus
Human immunodeficiency **virus**
Influenza **virus**
Theiler's murine encephalomyelitis **virus**
Treponema pallidum
(**treatment** of **infection** from; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)

IT 50-07-7, Mitomycin C 50-18-0, Cyclophosphamide 50-24-8, Prednisolone 50-44-2, 6-Mercaptopurine 50-76-0, Dactinomycin

50-91-9, 5-Fluorodeoxyuridine 51-21-8, 5-Fluorouracil 51-75-2, Mechlorethamine 52-24-4, Thiotepa 53-03-2, Prednisone 53-19-0, Mitotane 55-98-1, Busulfan 56-53-1, Diethylstilbestrol 57-22-7, Vincristine 57-63-6, Ethinyl estradiol 57-85-2, Testosterone propionate 58-05-9, Leucovorin 58-96-8, Uridine 59-05-2, Methotrexate 71-58-9, Medroxyprogesteroneacetate 76-43-7, Fluoxymesterone 125-84-8, Aminoglutethimide 127-07-1, Hydroxyurea 134-46-3, 5-Fluorodeoxyuridine monophosphate 147-94-4, Cytarabine 148-82-3, Melphalan 154-42-7, Thioguanine 154-93-8, Carmustine 305-03-3, Chlorambucil **320-67-2**, 5-Azacytidine 446-86-6, Azathioprine 595-33-5, Megestrol acetate 630-56-8, Hydroxyprogesterone caproate 645-05-6, Hexamethylmelamine 671-16-9, Procarbazine 865-21-4, Vinblastine 3778-73-2, Ifosfamide 4291-63-8, Cladribine 4342-03-4, Dacarbazine 9015-68-3, Asparaginase 10540-29-1, Tamoxifen 11056-06-7, Bleomycin 13010-47-4, Lomustine 13311-84-7, Flutamide 13909-09-6, Semustine 15663-27-1, Cisplatin 18378-89-7, Plicamycin 18883-66-4, Streptozocin 19767-45-4, Mesna 20830-81-3, Daunorubicin 23214-92-8, Doxorubicin 29767-20-2, Teniposide 33069-62-4, Paclitaxel 33419-42-0, Etoposide 41575-94-4, Carboplatin 51321-79-0 53643-48-4, Vindesine 53910-25-1, Pentostatin 56420-45-2, Epirubicin 58957-92-9, Idarubicin 61825-94-3, Oxaliplatin 65271-80-9, Mitoxantrone 71486-22-1, Vinorelbine 75607-67-9, Fludarabine phosphate 84449-90-1 95058-81-4, 2',2'-Difluorodeoxycytidine 97682-44-5, Irinotecan 114977-28-5, Docetaxel 123948-87-8, Topotecan 180288-69-1, Herceptin

RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)

(anti-proliferative agent; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity for treating hyper-proliferative disorder in combination with addnl. anti-proliferative agent)

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L73 ANSWER 10 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:946113 HCAPLUS

DOCUMENT NUMBER: 138:24647

TITLE: Preparation of 4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1H)-quinolinones and analogs as activators of caspases and inducers of apoptosis for treatment of cancer and other proliferative disorders

INVENTOR(S): Cai, Sui Xiong; Zhang, Han-Zhong; Drewe, John; Kasibhatla, Shailaja

PATENT ASSIGNEE(S): Cytovia, Inc., USA

SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002098425	A1	20021212	WO 2002-US17486	20020604

<--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,

KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,
MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE,
SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT,
BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG

EP 1404329 A1 20040407 EP 2002-741817
2002
0604
<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,
MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

US 2005165053 A1 20050728 US 2003-477953
2003
1118
<--

PRIORITY APPLN. INFO.: US 2001-295007P P
2001
0604
<--
WO 2002-US17486 W
2002
0604
<--

OTHER SOURCE(S): MARPAT 138:24647

GI



I



II

AB Title compds. I [wherein R1-R4 = independently H, halo, (hetero)aryl, (halo)alkyl, (hetero)cycloalkyl, alkenyl, alkynyl, (hetero)arylalkyl, (hetero)arylalkenyl, hydroxyalkyl, NO2, NH2, CN, acylamino, OH, SH, acyloxy, azido, (halo)alkoxy, aryloxy, arylalkoxy, carboxy, carbonylamido, or alkylthio; R5, R6, and R12 = independently H or (un)substituted alkyl; Ar1 = (un)substituted (hetero)aryl, (partially) saturated carbocyclyl, or (partially) saturated heterocyclyl; Ar2 = (un)substituted (hetero)aryl; and pharmaceutically acceptable salts or prodrugs thereof] were prepared as activators of caspases and inducers of apoptosis. For example, 2-amino-2'-fluoro-5-bromobenzophenone was treated with diketene in pyridine to give 3-acetyl-6-bromo-4-(2-fluorophenyl)-2(1H)-

quinolinone (89%). Condensation with m-nitrobenzaldehyde in EtOH produced the (3-nitrophenylpropenoyl)quinolinone II (R = NO2) in 42% yield. A related compound, II (R = H), activated caspase cascade activity with EC50 values of 849 nM and 1800 nM against human breast cancer cell lines T-47D and ZR-75-1, resp. Thus, I may be used to induce cell death in a variety of clin. conditions in which uncontrolled growth and spread of abnormal cells occurs, such as cancer and other proliferative disorders.

IT **320-67-2**, 5-Azacytidine
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(coadministration agent; coadministration of (arylpropenoyl)-2(1H)-quinolinone caspases activators with known cancer therapeutic agents for treatment of cancer)

RN 320-67-2 HCAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM A61K031-47

CC 27-17 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): **1**

IT **Infection**
(**viral**; preparation of (arylpropenoyl)-2(1H)-quinolinone caspases activators for treatment of cancer and other proliferative disorders)

IT 50-07-7, Mitomycin C 50-18-0, Cyclophosphamide 50-91-9, 5-Fluoro-2'-deoxyuridine 51-21-8, 5-Fluorouracil 55-98-1, Busulfan 57-22-7, Vincristine 59-05-2, Methotrexate 64-86-8, Colchicine 127-07-1, Hydroxyurea 147-94-4, Ara-C 148-82-3, Melphalan 154-42-7, Thioguanine 302-79-4, Retinoic acid 305-03-3, Chlorambucil **320-67-2**, 5-Azacytidine 459-86-9, Mitoguazone 865-21-4, Vinblastine 3778-73-2, Ifosfamide 5854-93-3, Alanosine 7689-03-4, Camptothecin 10540-29-1, Tamoxifen 11056-06-7, Bleomycin 15663-27-1, Cisplatin 21679-14-1, Fludarabine 23214-92-8, Doxorubicin 33069-62-4, Paclitaxel 33419-42-0, Etoposide 41575-94-4, Carboplatin 56420-45-2, Epirubicin 57576-44-0, Aclarubicin 58337-35-2, Elliptinium 65271-80-9, Mitoxantrone 83150-76-9, Octreotide 114977-28-5, Docetaxel 123948-87-8, Topotecan 174722-31-7, Rituxan 180288-69-1, Herceptin 216503-57-0, Campath 220127-57-1, Gleevec
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(coadministration agent; coadministration of (arylpropenoyl)-2(1H)-quinolinone caspases activators with known cancer therapeutic agents for treatment of cancer)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L73 ANSWER 11 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:946109 HCAPLUS

DOCUMENT NUMBER: 138:24718

TITLE: Preparation of 4-substituted-1-(arylmethylidene)thiosemicarbazides and 4-substituted-1-(arylcarbonyl)thiosemicarbazides as activators of caspases and inducers of apoptosis

INVENTOR(S): Cai, Sui Xiong; Nguyen, Bao Ngoc; Drewe, John; Reddy, P. Sanjeeva; Kasibhatla, Shailaja; Pervin, Azra

PATENT ASSIGNEE(S): Cytovia, Inc., USA

SOURCE: PCT Int. Appl., 93 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002098420	A1	20021212	WO 2002-US17108	20020531
			<--	
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1399159	A1	20040324	EP 2002-734605	20020531
			<--	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003045581	A1	20030306	US 2002-158827	20020603
			<--	
US 6794400	B2	20040921		

PRIORITY APPLN. INFO.:
US 2001-294641P P 20010601
<--
WO 2002-US17108 W 20020531
<--

OTHER SOURCE(S): MARPAT 138:24718

GI



I

AB The title compds. A1NR1C(:Q)NR2N:CR3A2 and A1NR1C(:Q)NR2NR3C(:O)A2

[A1, A2 = (un)substituted aryl, heteroaryl, etc.; Q = S, O; R1-R3 = H, alkyl, cycloalkyl] which may be used to induce cell death in a variety of clin. conditions in which uncontrolled growth and spread of abnormal cells occurs, were prepared Thus, reacting N1-bicyclo[2.2.1]hept-5-en-2-ylhydrazine-1-carbothioamide with 2-pyridinecarboxaldehyde in the presence of glacial AcOH in EtOH afforded 73% I which was identified as a potent caspase cascade activator and inducer of apoptosis in solid tumor cells (biol. data given).

IT **320-67-2**, 5-Azacytidine
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(preparation of 4-substituted-1-(arylmethylidene)thiosemicarbazides and 4-substituted-1-(arylcarbonyl)thiosemicarbazides for treating cancer in combination with)

RN 320-67-2 HCAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM A61K031-435

CC 28-13 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): **1**

IT **Infection**
(**viral, treatment** of; preparation of 4-substituted-1-(arylmethylidene)thiosemicarbazides and 4-substituted-1-(arylcarbonyl)thiosemicarbazides as activators of caspases and inducers of apoptosis)

IT 50-07-7, Mitomycin C 50-91-9, 5-Fluoro-2'-deoxyuridine 51-21-8, 5-Fluorouracil 55-98-1, Busulfan 57-22-7, Vincristine 59-05-2, Methotrexate 64-86-8, Colchicine 127-07-1, Hydroxyurea 147-94-4, Ara-C 148-82-3, Melphalan 154-42-7, Thioguanine 302-79-4, Retinoic acid 305-03-3, Chlorambucil **320-67-2**, 5-Azacytidine 459-86-9, Mitoguazone 865-21-4, Vinblastine 3778-73-2, Ifosfamide 5854-93-3, Alanosine 7689-03-4, Camptothecin 10540-29-1, Tamoxifen 11056-06-7, Bleomycin 15663-27-1, cis-Platin 21679-14-1, Fludarabine 23214-92-8, Doxorubicin 33069-62-4, Paclitaxel 33419-42-0, Etoposide 41575-94-4, Carboplatin 56420-45-2, Epirubicin 57576-44-0, Aclarubicin 58337-35-2, Elliptinium 65271-80-9, Mitoxantrone 83150-76-9, Octreotide 114977-28-5, Docetaxel 123948-87-8, Topotecan 174722-31-7, Rituxan 180288-69-1, Herceptin 216503-57-0, Campath 220127-57-1, Gleevec
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(preparation of 4-substituted-1-(arylmethylidene)thiosemicarbazides and 4-substituted-1-(arylcarbonyl)thiosemicarbazides for treating cancer in combination with)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L73 ANSWER 12 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:695764 HCAPLUS
DOCUMENT NUMBER: 137:210932
TITLE: Combination therapy for reduction of toxicity of chemotherapeutic agents
INVENTOR(S): Prendergast, Patrick T.
PATENT ASSIGNEE(S): Ire.
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002069949	A2	20020912	WO 2002-IB632	20020305
WO 2002069949	A3	20030605		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002169140	A1	20021114	US 2002-91855	20020306

<--

PRIORITY APPLN. INFO.: IE 2001-209 A 20010306

<--

AB Provided in the present invention are compds. suitable for treating neoplasms and tumors, viral, bacterial and parasite infections and combination therapy with these agents to lower the adverse side effects.

IT **320-67-2**, Azacytidine **62488-57-7**, 5,6-Dihydro-5-azacytidine **65886-71-7**, Ara-AC
RL: PAC (Pharmacological activity); **THU (Therapeutic use)** ; BIOL (Biological study); USES (Uses)
(combination therapy for reduction of toxicity of chemotherapeutic agents)

RN 320-67-2 HCAPLUS
CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 62488-57-7 HCAPLUS
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 65886-71-7 HCAPLUS
CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-β-D-arabinofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM A61K031-00
ICS A61K031-352; A61K031-12; A61K031-235; A61K009-127; A61K009-32; A61K009-16; A61K009-36; A61P035-00; A61P031-00; A61P031-04; A61P031-12; A61P031-18; A61P033-00; A61P037-06; A61K039-395; A61K039-42; A61K039-44; A61K031-7068; A61K031-7072
CC 1-6 (**Pharmacology**)
Section cross-reference(s): **63**
IT **Infection**
(**viral**; combination therapy for reduction of toxicity of chemotherapeutic agents)
IT 50-44-2, 6-Mercaptopurine 50-89-5, Thymidine, biological studies 50-91-9, Floxuridine 51-21-8, 5-Fluorouracil 54-05-7, Chloroquine 54-42-2, 5-Iodo-2'-deoxyuridine 58-96-8, Uridine 60-54-8, Tetracycline 68-94-0, Hypoxanthine 69-93-2, Uric acid, biological studies 70-00-8, Trifluorothymidine 73-24-5, Adenine, biological studies 80-08-0, Dapsone 83-89-6, Quinacrine 90-34-6, Primaquine 100-33-4, Pentamidine 130-95-0, Quinine 147-94-4, Cytosine arabinoside 154-42-7, 6-Thioguanine **320-67-2**, Azacytidine 342-69-8, 6-MMPR 443-48-1, Metronidazole 446-86-6, Azathioprine 500-92-5, Proguanil 518-28-5, Podophyllotoxin 605-23-2 1397-89-3, Amphotericin B 2365-40-4 3056-17-5, Stavudine 3416-05-5 3736-81-0, Diloxanide furoate 4291-63-8, Cladribine 4294-16-0, Benzyladenosine 4338-47-0, Furfuryladenosine 5536-17-4, Vidarabine 6025-53-2 7481-89-2, Ddc 7724-76-7 8064-90-2 13484-66-7 13484-67-8 15176-29-1, 5-Ethyl-2'-deoxyuridine 15185-43-0, DOTC 16412-36-5 18417-89-5, Sangivamycin 19387-91-8, Tinidazole 20268-93-3 20859-00-1 21679-14-1, Fludarabine 23169-37-1, 9-(4-Hydroxybutyl)guanine 23205-42-7, 3-Deazauridine 23256-30-6, Nifurtimox 30516-87-1,

3'-Azido-3'-deoxythymidine 30561-97-8 31441-78-8, Mercaptopurine 31698-14-3, Cyclocytidine 32115-08-5 34334-69-5, Cirsiliol 35943-35-2, Triciribine 36791-04-5, Ribavirin 37338-39-9 39809-25-1, Penciclovir 39960-81-1 51145-79-0 53230-10-7, Mefloquine 53910-25-1 53928-14-6 54532-47-7 55274-37-8 55582-99-5, N6-Adamantyladenosine 55583-00-1 59277-89-3, ACV 60084-10-8, Tiazofurin **62488-57-7**, 5,6-Dihydro-5-azacytidine 63968-64-9D, Artemisinin, derivs. **65886-71-7**, Ara-AC 69304-47-8 69304-48-9 69655-05-6, Dideoxyinosine 69756-53-2, Halofantrine 74886-33-2 77181-69-2 82410-32-0, Ganciclovir 84408-37-7, 6-Deoxyacyclovir 85087-20-3, Doxycline 86304-28-1, Buciclovir 87535-95-3 90301-59-0 92999-29-6 95058-81-4, Gemcitabine 95233-18-4, Atovaquone 97389-88-3 100817-46-7, Stibogluconic acid 101511-50-6 104227-87-4, Famciclovir 106941-25-7, PMEA 108436-80-2 113852-36-1 113852-37-2, Cidofovir 114088-58-3, PMEG 124832-26-4, Valacyclovir 127475-49-4 127759-89-1, Lobucavir 132216-69-4 132216-70-7 132240-40-5 134678-17-4, Lamivudine 136470-78-5, Abacavir 141204-94-6, Co-artemether 142340-99-6 143491-57-0, BW 1592 145514-04-1, DAPD 162600-97-7 168146-84-7, 1592U89 Succinate
RL: PAC (Pharmacological activity); **THU (Therapeutic use)** ; BIOL (Biological study); USES (Uses)
(combination therapy for reduction of toxicity of chemotherapeutic agents)

L73 ANSWER 13 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:521462 HCAPLUS
DOCUMENT NUMBER: 137:88442
TITLE: Incensole and furanogermacrens and compounds in treatment for inhibiting neoplastic lesions and microorganisms
INVENTOR(S): Shanahan-Pendergast, Elisabeth
PATENT ASSIGNEE(S): Ire.
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002053138	A2	20020711	WO 2002-IE1	20020102
			<--	
WO 2002053138	A3	20020919		
W: AE, AG, AT, AU, BB, BG, CA, CH, CN, CO, CU, CZ, LU, LV, MA, MD, UA, UG, US, VN, YU, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, AT, BE, CH, CY, DE, ES, FI, ML, MR, NE, SN, TD, TG				
AU 2002219472	A1	20020716	AU 2002-219472	20020102
			<--	
EP 1351678	A2	20031015	EP 2002-727007	20020102
			<--	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004092583	A1	20040513	US 2004-250535	20040102

PRIORITY APPLN. INFO.: IE 2001-2 A 2001 0102
WO 2002-IE1 W 2002 0102

OTHER SOURCE(S): MARPAT 137:88442

AB The invention discloses the use of incensole and/or furanogermacrens, derivs. metabolites and precursors thereof in the treatment of neoplasia, particularly resistant neoplasia and immunodysregulatory disorders. These compds. can be administered alone or in combination with conventional chemotherapeutic, antiviral, antiparasite agents, radiation and/or surgery. Incensole and furanogermacren and their mixture showed antitumor activity against various human carcinomas and melanomas and antimicrobial activity against Staphylococcus aureus and Enterococcus faecalis.

IT **320-67-2**, Azacitidine **2353-33-5**, Decitabine **62488-57-7** **65886-71-7**, Fazarabine
RL: PAC (Pharmacological activity); **THU (Therapeutic use)** ; BIOL (Biological study); USES (Uses)
(pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

RN 320-67-2 HCAPLUS
CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 2353-33-5 HCAPLUS
CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 62488-57-7 HCAPLUS
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 65886-71-7 HCAPLUS
CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-β-D-arabinofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM A61K031-00
CC 1-6 (**Pharmacology**)
Section cross-reference(s): **10, 63**
IT **Virus**
(lipid envelope, **treatment** of immunodysregulation condition caused by infection with; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
IT Adeno-associated **virus**
Balantidium
Balantidium coli
Borrelia
Campylobacter
Candida
Coronavirus
Cryptococcus (fungus)
Cryptosporidium
DNA **viruses**
Entamoeba
Entamoeba histolytica
Filovirus
Flavivirus
Haemophilus
Hantavirus
Human papillomavirus
Human parainfluenza **virus**
Human poliovirus
Influenza **virus**
Legionella
Leishmania
Leishmania braziliensis
Leishmania donovani
Leishmania mexicana
Leishmania tropica
Listeria
Measles **virus**
Mycoplasma

Papillomavirus
Pestivirus
Picornaviridae
Plasmodium berghei
Plasmodium falciparum
Plasmodium malariae
Plasmodium ovale
Plasmodium vivax
Pneumocystis
Pneumocystis carinii
Poxviridae
Pseudomonas
RNA **viruses**
Respiratory syncytial **virus**
Retroviridae
Rhinovirus
Rubivirus
Salmonella
Shigella
Staphylococcus
Streptococcus
Togaviridae
Toxoplasma
Toxoplasma gondii
Trichomonas
Trichomonas vaginalis
Trypanosoma
Trypanosoma brucei
Trypanosoma cruzi
Trypanosoma gambiense
Trypanosoma rhodesiense
Vibrio
Yersinia
(**treatment** of immunodysregulation condition caused by infection with; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT **Infection**
(**viral, treatment** of immunodysregulation condition caused by; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT 50-07-7, Mutamycin 50-18-0, Cyclophosphamide 50-28-2, Estradiol, biological studies 50-35-1, Thalidomide 50-76-0, Dactinomycin 50-91-9, Floxuridine 51-21-8, Fluorouracil 51-75-2, Mechlorethamine 52-24-4, Thiotepa 53-19-0, Mitotane 53-43-0, DHEA 53-79-2, Puromycin 54-71-7, Pilocarpine hydrochloride 54-91-1, Pipobroman 55-21-0D, Benzamide, N-substituted compds. 55-86-7, Mechlorethamine Hydrochloride 55-86-7D, Nitrogen mustard, derivs. 55-98-1, Busulfan 56-53-1, Diethylstilbestrol 57-22-7, Vincristine 57-63-6, Ethinyl oestradiol 57-83-0, Progesterone, biological studies 58-05-9, Leucovorin 58-58-2, Puromycin Hydrochloride 59-05-2, Methotrexate 66-75-1, Uracil Mustard 83-89-6, Acriquine 101-60-0, Porphyrin 106-60-5, Aminolevulinic acid 114-70-5, Sodium phenylacetate 122-79-2, Phenylacetate 125-45-1, Azetepa 125-84-8, Aminoglutethimide 127-07-1, Hydroxyurea 143-67-9, Vinblastine Sulfate 145-63-1, Suramin 147-94-4, Cytarabine 148-82-3, Melphalan 154-42-7, Thioguanine 154-93-8, Carmustine 302-49-8, Uredepa 302-79-4, Tretinoin 305-03-3, Chlorambucil **320-67-2**, Azacitidine 359-83-1, Pentazocine 364-62-5, Metoclopramide 366-70-1, Procarbazine Hydrochloride 378-44-9, Betamethasone 423-55-2, Perflubron 459-86-9, Mitoguazone 465-65-6, Naloxone 472-15-1, Betulinic acid 481-29-8, Epiandrosterone 518-28-5, Podophyllotoxin 520-85-4, Medroxyprogesterone 521-12-0, Dromostanolone Propionate 536-59-4, Perillyl alcohol 548-04-9, Hypericin 566-48-3, Formestane 569-57-3, Chlorotrianisene 578-95-0D, Acridone,

imidazo derivs. 578-95-0D, Acridone, propylbis derivs. 595-33-5, Megestrol Acetate 645-05-6, Altretamine 646-08-2, β-Alethine 671-16-9, Procarbazine 801-52-5, Porfiromycin 865-21-4, Vinblastine 911-45-5, Clomifene 968-93-4, Testolactone 1271-19-8, Titanocene dichloride 1402-81-9, Ambomycin 1403-99-2, Mitogillin 1404-00-8, Mitomycin 1404-15-5, Nogalamycin 1404-20-2, Peliomycin 1404-64-4, Sparsomycin 1661-29-6, Meturedepa 1972-08-3, Dronabinol 1980-45-6, Benzodepa 2068-78-2, Vincristine Sulfate 2353-33-5, Decitabine 2508-89-6 2608-24-4, Piposulfan 2809-21-4D, Etidronic acid, rhenium-186 complexes 2919-66-6, Melengestrol acetate 2998-57-4, Estramustine 2998-57-4D, Estramustine, analogs 3073-59-4, Hexamethylene bisacetamide 3094-09-5, Doxifluridine 3562-63-8, Megestrol 3778-73-2, Ifosfamide 3930-19-6, Streptonigrin 4105-38-8 4291-63-8, Cladribine 4342-03-4, Dacarbazine 4342-07-8 4803-27-4, Anthramycin 5072-26-4, Buthionine sulfoximine 5373-42-2, Thaliblastine 5508-58-7, Andrographolide 5579-27-1, Simtrazene 5581-52-2, Thiamiprine 5696-17-3, Epipropidine 6157-87-5, Trestolone Acetate 7281-31-4, Vinglycinate Sulfate 7440-06-4D, Platinum, lipophilic compds. or complexes 7440-06-4D, Platinum, triamine complexes 7644-67-9, Azotomycin 7689-03-4D, Camptothecin, derivs. 7724-76-7, Riboprine 7761-45-7, Metoprine 8052-16-2, Cactinomycin 9002-71-5, Thyroid-stimulating hormone 9014-02-2, Zinostatin 9014-42-0, Thrombopoietin 9014-42-0D, Thrombopoietin, mimetics 9015-68-3, Asparaginase 9027-98-9 9041-93-4, Bleomycin Sulfate 9050-67-3, Sizofiran 10043-49-9, Gold-198, biological studies 10087-89-5, Enpromate 10318-26-0, Mitolactol 10403-51-7, Mitindomide 10540-29-1, Tamoxifen 11002-22-5, Apurinic acid 11029-06-4, Elemene 11043-98-4, Mitocromin 11043-99-5, Mitomalcin 11056-06-7, Bleomycin 11056-12-5, Cirolemycin 11056-14-7, Mitocarcin 11056-15-8, Mitosper 12713-07-4D, Verdin, compds. 13010-47-4, Lomustine 13311-84-7, Flutamide 13494-90-1, Gallium nitrate 13665-88-8, Mopidamol 13909-09-6, Semustine 14769-73-4, Levamisole 15475-56-6, Methotrexate Sodium 15639-50-6, Safingol 15663-27-1, Cisplatin 17021-26-0, Calusterone 17902-23-7, Tegafur 18378-89-7, Plicamycin 18416-85-8, Lombricine 18556-44-0, Vinrosidine Sulfate 18588-57-3, Etoprine 18883-66-4, Streptozocin 19916-73-5, O6-Benzylguanine 20098-14-0, Idramantone 20537-88-6, Amifostine 20638-84-0, Retinamide 20830-81-3, Daunorubicin 21059-48-3, Veramine 21679-14-1, Fludarabine 22668-01-5, Etanidazole 23214-92-8, Doxorubicin 23541-50-6, Daunorubicin Hydrochloride 23593-75-1, Clotrimazole 24280-93-1, Mycophenolic Acid 24584-09-6, Dexrazoxane 25316-40-9, Adriamycin 27302-90-5, Oxisuran 27314-97-2, Tirapazamine 27548-93-2D, Baccatin III, derivs. 27686-84-6, Masoprocol 29069-24-7, Prednimustine 29767-20-2, Teniposide 30303-65-2, Docosanol 30387-51-0, Asperlin 30868-30-5, Pyrazofurin 31430-18-9, Nocodazole 31441-78-8, Mercaptopurine 32954-58-8, Ipomeanol 33069-62-4, Paclitaxel 33069-62-4D, Paclitaxel, analogs and derivs. 33419-42-0, Etoposide 35301-24-7, Cedefingol 35846-53-8, Maytansine 35943-35-2, Triciribine 36508-71-1, Zorubicin Hydrochloride 37717-21-8, Flurocitabine 38270-90-5, Strontium Chloride Sr 89 38321-02-7, Dexverapamil 39325-01-4, Picibanil 40391-99-9, Pamidronic acid 41575-94-4, Carboplatin 41729-52-6, Dezaguanine 41992-22-7, Spirogermanium Hydrochloride 42228-92-2, Acivicin 42616-25-1, Methioninase 50264-69-2, Lonidamine 51264-14-3, Amsacrine 51321-79-0, Sparfosic acid 52128-35-5, Trimetrexate 52205-73-9, Estramustine Phosphate Sodium 52794-97-5, Carubicin Hydrochloride 53643-48-4, Vindesine 53714-56-0, Leuprolide 53910-25-1, Pentostatin 54081-68-4, Vinleurosine Sulfate 54824-17-8, Mitonafide 55435-65-9, Acodazole Hydrochloride 56390-09-1, Epirubicin Hydrochloride 56420-45-2, Epirubicin

56605-16-4, Spiromustine 56741-95-8, Bropirimine 57381-26-7, Irsogladine 57576-44-0, Aclarubicin 57773-63-4, Triptorelin 57773-65-6, Deslorelin 57852-57-0, Idamycin 57998-68-2, Diaziquone 58066-85-6, Miltefosine 58525-82-9, Azatyrosine 58957-92-9, Idarubicin 58970-76-6, Ubenimex 59653-73-5, Teroxirone 59917-39-4, Vindesine Sulfate 59989-18-3, 5-Ethynyluracil 60084-10-8, Tiazofurin 60203-57-8, Prostaglandin J2 60940-34-3, Ebselen 61825-94-3, Oxaliplatin 61966-08-3, Triciribine Phosphate 62304-98-7, Thymalfasin 62435-42-1, Perfosfamide **62488-57-7** 62816-98-2, Ormaplatin 62928-11-4, Iproplatin 63590-19-2, Balanol 63612-50-0, Nilutamide 63950-06-1, Esorubicin Hydrochloride
RL: PAC (Pharmacological activity); **THU (Therapeutic use)** ; BIOL (Biological study); USES (Uses)
(pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT 65057-90-1, Talisomycin 65093-40-5, Cytarabine ocfosfate 65222-35-7, Pazelliptine 65271-80-9, Mitoxantrone 65646-68-6, Fenretinide 65807-02-5, Goserelin **65886-71-7**, Fazarabine 66569-27-5, Sparfosate Sodium 66849-34-1, Dexifosfamide 67699-41-6, Vinzolidine Sulfate 68278-23-9, Eflornithine Hydrochloride 68475-42-3, Anagrelide 69839-83-4, Didox 70052-12-9, Eflornithine 70384-29-1, Peplomycin Sulfate 70476-82-3, Mitoxantrone Hydrochloride 70641-51-9, Edelfosine 70711-40-9, Ametantrone Acetate 71294-60-5, Rohitukine 71439-68-4, Bisantrene Hydrochloride 71486-22-1, Vinorelbine 71522-58-2, Forfenimex 71628-96-1, Menogaril 72238-02-9D, Retelliptine, demethyl derivs. 72496-41-4, Pirarubicin 72629-69-7, Sarcophytol A 72732-56-0, Piritrexim 72741-87-8, Swainsonine 73105-03-0, Pentamustine 74149-70-5, Parabactin 74381-53-6, Leuprolide Acetate 74790-08-2, Spiroplatin 75219-46-4, Atrimustine 75330-75-5, Lovastatin 75607-67-9, Fludarabine Phosphate 75775-33-6D, Purpurin, compds. 75957-60-7, Splenopentin 76932-56-4, Nafarelin 77016-85-4, Plomestane 77327-05-0, Didemnin B 77599-17-8, Panomifene 77858-21-0, Velaresol 78113-36-7, Romurtide 78186-34-2, Bisantrene 79778-41-9, Neridronic acid 79831-76-8, Castanospermine 80451-05-4, Cecropin B 80576-83-6, Edatrexate 80663-95-2 80841-47-0, Asulacrine 81424-67-1, Caracemide 81965-43-7, SarCNU 82230-03-3, Carbetimer 82413-20-5, Droloxifene 82707-54-8, Neutral endopeptidase 82855-09-2D, Combretastatin, analogs 82952-64-5, Trimetrexate Glucuronate 83086-73-1, Tubulozole Hydrochloride 83150-76-9, Octreotide 83200-11-7, Vinepidine Sulfate 83519-04-4, Ilmofosine 83997-75-5, Iododoxorubicin 84030-84-2, Telluropyrylium 84088-42-6, Roquinimex 84371-65-3, Mifepristone 84412-94-2, Ruboxyl 85465-82-3, Thymotrinan 85622-93-1, Temozolomide 85754-59-2, Ambamustine 85969-07-9, Budotitane 85977-49-7, Tauromustine 86976-56-9, Betaclamycins 87005-03-6, Panaxytriol 87434-82-0, Dezaguanine Mesylate 87806-31-3, Porfimer Sodium 87810-56-8, Fostriecin 87860-39-7, Fostriecin Sodium 88303-60-0, Losoxantrone 88303-61-1, Losoxantrone Hydrochloride 89565-68-4, Tropisetron 89778-26-7, Toremifene 89778-27-8, Toremifene Citrate 90357-06-5, Bicalutamide 90996-54-6, Rhizoxin 92047-76-2, Tetrachlorodecaoxide 92118-27-9, Fotemustine 92788-10-8, Rogletimide 92803-82-2, Aphidicolin glycinate 94079-80-8, Cicaprost 95058-81-4, Gemcitabine 95734-82-0, Nedaplatin 95933-72-5, Amidox 96201-88-6, Brequinar Sodium 96301-34-7, Atamestane 96346-61-1, Onapristone 96389-68-3, Crisnatol 96389-69-4, Crisnatol Mesylate 96392-96-0, Dexormaplatin 96892-57-8, Hepsulfam 97068-30-9, Elsamitrucin 97534-21-9, Merbarone 97682-44-5, Irinotecan 97752-20-0, Droloxifene Citrate 97919-22-7 98319-26-7, Finasteride 98383-18-7, Ecomustine 98631-95-9, Sobuzoxane 99009-20-8, Pyrazoloacridine 99011-02-6, Imiquimod

99283-10-0, Molgramostim 99614-02-5, Ondansetron 100286-90-6, Irinotecan Hydrochloride 100324-81-0, Lisofylline 102396-24-7, Jasplakinolide 102676-31-3, Fadrozole Hydrochloride 102676-47-1, Fadrozole 102822-56-0, Mannostatin A 103222-11-3, Vapreotide 103612-80-2 104493-13-2, Adecypenol 105118-12-5, Piroxantrone Hydrochloride 105149-04-0, Osaterone 105615-58-5, Oxaunomycin 105844-41-5, Plasminogen activator inhibitor 106096-93-9D, Basic fibroblast growth factor, saporin conjugates 106400-81-1, Lometrexol 107000-34-0, Zanoterone 107256-99-5, Tamoxifen methiodide 107868-30-4, Exemestane 108736-35-2, Lanreotide 108852-90-0, Nemorubicin 109837-67-4, Cycloplatam 110267-81-7, Amrubicin 110311-27-8, Sulofenur 110314-48-2, Adozelesin 110690-43-2, Emitefur 110942-02-4, Aldesleukin 110942-08-0, Luprolide 111490-36-9, Zeniplatin 111523-41-2, Enloplatin 112515-43-2, Topsentin 112522-64-2, Acetyldinaline 112809-51-5, Letrozole 112859-71-9, Fluasterone 112887-68-0, Raltitrexed 112965-21-6, Calcipotriol 114084-78-5, Ibandronic acid 114285-68-6, Lentinan sulfate 114517-02-1, Fosquidone 114977-28-5, Taxotere 115150-59-9, Antagonist G 115308-98-0, Tallimustine 115566-02-4, Bistratene A 115575-11-6, Liarozole 115956-12-2, Dolasetron 116057-75-1, Idoxifene 117048-59-6, Combretastatin A4 117091-64-2, Etoposide Phosphate 118292-40-3, Tazarotene 119169-78-7, Epristeride 119413-54-6, Topotecan Hydrochloride 119813-10-4, Carzelesin 120287-85-6, Cetrorelix 120408-07-3, Lometrexol Sodium 120500-15-4, Leinamycin 120511-73-1, Anastrozole 120685-11-2, Benzoylstaurosporine 121181-53-1, Filgrastim 121263-19-2, Calphostin C 121288-39-9, Loxoribine 121547-04-4, Mirimostim 122111-03-9, Gemcitabine Hydrochloride 122341-38-2, Temoporfin 122431-96-3 122898-63-9, Phenazinomycin 123040-69-7, Azasetron 123258-84-4, Itasetron 123760-07-6, Zinostatin stimalamer 123774-72-1, Sargramostim 123830-79-5, Teloxantrone Hydrochloride 123948-87-8, Topotecan 124012-42-6, Galocitabine 124689-65-2D, Cryptophycin A, derivs. 124784-31-2, Erbulozole 124904-93-4, Ganirelix 125317-39-7, Vinorelbine Tartrate 125392-76-9, Acylfulvene 125533-88-2, Mofarotene 126297-39-0, Lissoclinamide 7 126443-96-7, Napavin 127984-74-1, Lanreotide Acetate 128505-88-4, Naphterpin 128768-09-2, Placetin A 128768-11-6, Placetin B 129497-78-5, Verteporfin 129564-92-7, Azatoxin 129655-21-6, Bizelesin 129731-10-8, Vorozole 130167-69-0, Pegaspargase 130288-24-3, Duocarmycin SA 130364-39-5, Rubiginone B1 130370-60-4, Batimastat 131190-63-1, Saintopin 132036-88-5, Ramosetron 132073-72-4, Tetrazomine 133432-71-0, Peldesine 134088-74-7, Nartograstim 134381-30-9, Conagenin 134523-84-5 134633-29-7, Tecogalan Sodium 134861-62-4, Dioxamycin 135257-45-3, Crambescidin 816 135381-77-0, Flezelastine 135383-02-7, Stipiamide 135558-11-1, Lobaplatin 135819-69-1 135968-09-1, Lenograstim 137018-54-3, Okicenone 137099-09-3, Turosteride 137219-37-5, Dehydrodidemnin B 137647-92-8, Axinastatin 1 137964-32-0 139755-79-6, Safingol Hydrochloride 140207-93-8, Pentosan polysulfate sodium 140703-49-7, Meterelin 142880-36-2, Ilomastat 144885-51-8, Sodium borocaptate 144916-42-7, Sonermin 145124-30-7, Bisnafide dimesylate 145858-50-0, Liarozole Hydrochloride 146426-40-6, Flavopiridol 148317-76-4, Oracin 148584-53-6 148717-58-2, Palauamine 148717-90-2, Squalamine 149204-42-2, Kahalalide F
RL: PAC (Pharmacological activity); **THU (Therapeutic use)** ; BIOL (Biological study); USES (Uses)
(pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

L73 ANSWER 14 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:488245 HCAPLUS
DOCUMENT NUMBER: 137:57593

TITLE: Compositions and methods using alkyl- and phospholipid-drug conjugates for double-targeting **virus infections** and cancer cells

INVENTOR(S): Kucera, Louis S.; Fleming, Ronald A.; Ishaq, Khalid S.; Kucera, Gregory L.; Morris-Natschke, Susan L.

PATENT ASSIGNEE(S): Wake Forest University School of Medicine, USA; University of North Carolina At Chapel

SOURCE: U.S. Pat. Appl. Publ., 35 pp., Cont.-in-part of U.S. Ser. No. 693,658.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002082242	A1	20020627	US 2001-844201	20010427
US 7026469	B2	20060411		
US 6670341	B1	20031230	US 2000-693658	20001019
CA 2445565	AA	20021107	CA 2002-2445565	20020426
WO 2002087465	A2	20021107	WO 2002-US13338	20020426
WO 2002087465	A3	20031211		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1389970	A2	20040225	EP 2002-721822	20020426
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005505499	T2	20050224	JP 2002-584819	20020426
US 2004161398	A1	20040819	US 2003-748738	20031230
PRIORITY APPLN. INFO.:			US 2000-693658 A2	20001019

<--
US 1999-162290P P
1999
1028
<--
US 2001-844201 A
2001
0427
<--
WO 2002-US13338 W
2002
0426
<--

OTHER SOURCE(S): MARPAT 137:57593

GI



I

AB The invention includes compns. and methods useful for **treatment** of a **virus infection** in a mammal by double-targeting the virus (i.e. targeting the virus at more than one stage of the virus life cycle) and thereby inhibiting virus replication. The compns. of the invention include compds., which comprise a phosphocholine moiety covalently conjugated with one or more therapeutic agents (e.g. nucleoside analog, protease inhibitor, etc.) to a lipid backbone. The invention also includes pharmaceutical compns. for use in **treatment** of a **virus infection** in mammals. The methods of the invention comprise administering a compound of the invention, a pharmaceutically acceptable salt or a prodrug thereof, or a pharmaceutical composition of the invention, in an amount effective to treat the infection, to a mammal infected with a virus. Addnl., the invention includes compns. and methods useful for combating a cancer in a mammal and facilitating delivery of a therapeutic agent to a mammalian cell. The compns. of the invention include compds., which comprise an alkyl lipid or phospholipid moiety covalently conjugated with a therapeutic agent (e.g., a nucleoside analog). The invention also includes pharmaceutical compns. for combating cancer and facilitating delivery of a therapeutic agent to a mammalian cell. The methods of the invention comprise administering a compound of the invention, a pharmaceutically acceptable salt or a prodrug thereof, or a pharmaceutical composition of the invention, in an amount effective to combat a cancer or to facilitate delivery of a therapeutic agent to a mammalian cell. Preparation of INK-20 (I) is described.

IT **320-67-2D**, 5-Azacytidine, alkyl- and phospholipid conjugates
RL: PAC (Pharmacological activity); **THU (Therapeutic use)** ; BIOL (Biological study); USES (Uses)
(alkyl- and phospholipid-drug conjugates for double-targeting **virus infections** and cancer cells)

RN 320-67-2 HCAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM A61K031-675
ICS A61K031-66; C07F009-10
INCL 514079000; X51-410.2; X51-411.9; X51-412.7; X51-412.9; X55-815.9; X55-817.0; X55-817.7
CC 1-12 (**Pharmacology**)
Section cross-reference(s): 33, **63**
IT Antitumor agents
Antiviral agents
(alkyl- and phospholipid conjugates; alkyl- and phospholipid-drug conjugates for double-targeting **virus infections** and cancer cells)
IT Nucleoside analogs
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkyl- and phospholipid conjugates; alkyl- and phospholipid-drug conjugates for double-targeting **virus infections** and cancer cells)
IT Astrocyte
Blood-brain barrier
Brain, disease
Carcinoma
Cardiovascular agents
Cardiovascular system, disease
Central nervous system, disease
Cytomegalovirus
Drug bioavailability
Drug delivery systems
Drug resistance
Hepatitis A virus
Hepatitis B virus
Hepatitis C virus
Hepatitis E virus
Hepatitis GB virus C/G
Hepatitis delta virus
Hepatitis virus
Herpesviridae
Human
Human herpesvirus
Human herpesvirus 1
Human herpesvirus 2
Human herpesvirus 3
Human herpesvirus 4
Human herpesvirus 6
Human herpesvirus 7
Human herpesvirus 8
Human immunodeficiency virus
Human immunodeficiency virus 1
Human immunodeficiency virus 2
Kidney, disease
Leukemia
Liver, disease
Lymphatic system, disease
Lymphocyte
Lymphoma

Nervous system agents
Neuroglia
Rhinovirus
Sarcoma
(alkyl- and phospholipid-drug conjugates for double-targeting **virus infections** and cancer cells)

IT Central nervous system
(cell; alkyl- and phospholipid-drug conjugates for double-targeting **virus infections** and cancer cells)

IT Reproductive system
(disease; alkyl- and phospholipid-drug conjugates for double-targeting **virus infections** and cancer cells)

IT Lipids, biological studies
Phospholipids, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug conjugates; alkyl- and phospholipid-drug conjugates for double-targeting **virus infections** and cancer cells)

IT Biological transport
(drug; alkyl- and phospholipid-drug conjugates for double-targeting **virus infections** and cancer cells)

IT Nerve, neoplasm
(neuroblastoma; alkyl- and phospholipid-drug conjugates for double-targeting **virus infections** and cancer cells)

IT Drugs
(phospholipid conjugates; alkyl- and phospholipid-drug conjugates for double-targeting **virus infections** and cancer cells)

IT Drug delivery systems
(prodrugs; alkyl- and phospholipid-drug conjugates for double-targeting **virus infections** and cancer cells)

IT Neoplasm
(solid; alkyl- and phospholipid-drug conjugates for double-targeting **virus infections** and cancer cells)

IT 144114-21-6, HIV-1 Protease
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(alkyl- and phospholipid-drug conjugates for double-targeting **virus infections** and cancer cells)

IT 141790-23-0, BM 21-1290
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkyl- and phospholipid-drug conjugates for double-targeting **virus infections** and cancer cells)

IT 340130-57-6P, INK 20
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(alkyl- and phospholipid-drug conjugates for double-targeting **virus infections** and cancer cells)

IT 50-44-2D, 6-Mercaptopurine, alkyl- and phospholipid conjugates 50-91-9D, alkyl- and phospholipid conjugates 147-94-4D, Ara-C, alkyl- and phospholipid conjugates **320-67-2D**, 5-Azacytidine, alkyl- and phospholipid conjugates 4291-63-8D, Cladribine, alkyl- and phospholipid conjugates 21679-14-1D, Fludarabine, alkyl- and phospholipid conjugates 30516-87-1D, AZT, alkyl- and phospholipid conjugates 95058-81-4D, Gemcitabine, alkyl- and phospholipid conjugates 340130-55-4, INK 17 340130-56-5, INK 18 340130-58-7, INK 21 340130-59-8, INK 22 340130-60-1, INK 23 340130-61-2, INK 24 340130-62-3, INK

25 340130-63-4, INK 26 340130-64-5, INK 19
RL: PAC (Pharmacological activity); **THU (Therapeutic use)**
; BIOL (Biological study); USES (Uses)
(alkyl- and phospholipid-drug conjugates for double-targeting **virus infections** and cancer cells)

IT 9001-92-7, Protease 9068-38-6, Reverse transcriptase
433935-36-5, Polynucleotide polymerase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors, alkyl- and phospholipid conjugates; alkyl- and phospholipid-drug conjugates for double-targeting **virus infections** and cancer cells)

IT 313343-77-0P 439113-17-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP
(Preparation); RACT (Reactant or reagent)
(preparation and reaction; alkyl- and phospholipid-drug conjugates for double-targeting **virus infections** and cancer cells)

IT 1663-67-8, Malonyl chloride 30516-87-1, AZT 439077-64-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction; alkyl- and phospholipid-drug conjugates for double-targeting **virus infections** and cancer cells)

L73 ANSWER 15 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:458415 HCAPLUS
DOCUMENT NUMBER: 138:100377
TITLE: Identification of active antiviral compounds against a New York isolate of West Nile virus
AUTHOR(S): Morrey, John D.; Smee, Donald F.; Sidwell, Robert W.; Tseng, Christopher
CORPORATE SOURCE: Department of Animal, Dairy, and Veterinary Sciences, Institute for Antiviral Research, Utah State University, Logan, UT, 84322-4700, USA
SOURCE: Antiviral Research (**2002**), 55(1), 107-116.
CODEN: ARSRDR; ISSN: 0166-3542
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The recent West Nile virus (WNV) outbreak in the United States has increased the need to identify effective therapies for this disease. A chemotherapeutic approach may be a reasonable strategy because the **virus infection** is typically not chronic and antiviral drugs have been identified to be effective in vitro against other flaviviruses. A panel of 34 substances was tested against infection of a recent New York isolate of WNV in Vero cells and active compds. were also evaluated in MA-104 cells. Some of these compds. were also evaluated in Vero cells against the 1937 Uganda isolate of the WNV. Six compds. were identified to be effective against virus-induced CPE with 50% effective concns. (EC50) less than 10 μg/mL and with a selectivity index (SI) of greater than 10. Known inhibitors of orotidine monophosphate decarboxylase and inosine monophosphate dehydrogenase involved in the synthesis of GTP, UTP, and TTP were most effective. The compds. 6-azauridine, 6-azauridine triacetate, cyclopententylcytosine (CPE-C), mycophenolic acid and pyrazofurin appeared to have the greatest activities against the New York isolate, followed by 2-thio-6-azauridine. Anti-WNV activity of 6-azauridine was confirmed by virus yield reduction assay when the assay was performed 2 days after initial infection in Vero cells. The neutral red assay mean EC50 of ribavirin was only 106 μg/mL with a mean SI of 9.4 against the New York isolate and only slightly more effective against the Uganda isolate. There were some differences in the drug sensitivities of the New York and Uganda isolates, but when comparisons were made by

categorizing drugs according to their modes of action, similarities of activities between the two isolates were identified.

IT **320-67-2**, 5-Azacytidine **62488-57-7**
RL: PAC (Pharmacological activity); **THU (Therapeutic use)** ; BIOL (Biological study); USES (Uses)
(identification of active antiviral compds. against a New York isolate of West Nile virus)

RN 320-67-2 HCAPLUS
CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 62488-57-7 HCAPLUS
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



CC 1-5 (**Pharmacology**)

IT 54-25-1, 6-Azauridine 141-90-2, 2-Thiouracil 145-63-1, Suramin 316-46-1, 5-Fluorouridine **320-67-2**, 5-Azacytidine 548-04-9, Hypericin 2169-64-4, 6-Azauridine triacetate 13877-76-4, Formycin B 20201-55-2, 6-Bromotoyocamycin 24280-93-1, Mycophenolic acid 27089-56-1, 2-Thio-6-azauridine 30868-30-5, Pyrazofurin 36791-04-5, Ribavirin 42400-25-9 54262-83-8, (S)-9-(2,3-Dihydroxypropyl)adenine 56039-11-3, 3-Deazaguanosine 60084-10-8, Tiazofurin **62488-57-7** 83705-13-9, Selenazofurin 90597-20-9 90597-22-1, Cyclopentenylcytosine 102052-95-9, 3-Deazaneplanocin A 102977-57-1 119567-79-2, Ribamidine
RL: PAC (Pharmacological activity); **THU (Therapeutic use)** ; BIOL (Biological study); USES (Uses)
(identification of active antiviral compds. against a New York isolate of West Nile virus)

REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L73 ANSWER 16 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:582317 HCAPLUS
DOCUMENT NUMBER: 135:164441
TITLE: Tumor cell chemosensitization by deoxycytidine

kinase phosphorylation of pyrimidine and purine deoxynucleoside prodrugs
INVENTOR(S): Fine, Howard A.; Kufe, Donald W.; Manome, Yoshinobu
PATENT ASSIGNEE(S): Dana-Farber Cancer Institute, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 17 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2001012835	A1	20010809	US 1998-65933	1998 0424
US 6423692	B2	20020723		

PRIORITY APPLN. INFO.: US 1997-44314P P 1997 0424

AB The present invention is directed to a method of increasing the effectiveness of mols. that are phosphorylated in their active state. This is accomplished by transducing cells with the gene for deoxycytidine kinase resulting in the chemosensitization of such cells which are targets for those mols. Preferably, the target cells are virally infected cells and/or tumor cells. Preferred tumor cells are solid tumor cells such as brain tumors. Deoxycytidine kinase (dCK) is an enzyme that catalyzes the phosphorylation of a variety of pyrimidine and purine deoxynucleosides to their corresponding nucleotide. A number of the abovementioned deoxynucleoside mols. when phosphorylated by dCK are activated" and display an antineoplastic and/or antiviral activity. We have now identified a new method for enhancing the effectiveness of a group of mols. that are phosphorylated or capable of phosphorylation by dCK. Thus, we have identified a new chemosensitization "gene/ prodrug" system. This system involves using dCK as the gene and mols. activated by dCK phosphorylation as the prodrug. The mols. that can be used are those that can be used against leukemia cells. These mols. include ara-C, dFdC, cladribine, zalcitabine, and fludarabine. Phosphorylation of these mols. yields the corresponding nucleoside triphosphate which exhibits an antiviral, antineoplastic, etc. activity. One preferred way of increasing the effectiveness of these mols. is by increasing the sensitization of the target cells to these mols. That can be accomplished by increasing the levels of dCK expressed. We have discovered that one way of accomplishing this is by introducing a dCK gene into a cell, e.g. by transducing a target cell with a gene encoding dCK, preferably the human dCK gene.

IT **2353-33-5**, 5-Aza-2'-deoxycytidine
RL: BPR (Biological process); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); USES (Uses)
(tumor cell chemosensitization by deoxycytidine kinase phosphorylation of pyrimidine and purine deoxynucleoside prodrugs)

RN 2353-33-5 HCAPLUS
CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM A61K031-70
INCL 514044000
CC 9-2 (Biochemical Methods)
Section cross-reference(s): 1, 7
IT **Infection**
(**viral**; tumor cell chemosensitization by deoxycytidine kinase phosphorylation of pyrimidine and purine deoxynucleoside prodrugs)
IT 147-94-4, Ara-C **2353-33-5**, 5-Aza-2'-deoxycytidine 4291-63-8, Cladribine 7481-89-2, Zalcitabine 21679-14-1, Fludarabine 95058-81-4
RL: BPR (Biological process); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); USES (Uses)
(tumor cell chemosensitization by deoxycytidine kinase phosphorylation of pyrimidine and purine deoxynucleoside prodrugs)

L73 ANSWER 17 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:911409 HCAPLUS
DOCUMENT NUMBER: 134:69876
TITLE: Subcellular distribution of uncoupling proteins as a marker of cell proliferation capacity and its manipulation in tumor therapy
INVENTOR(S): Newell, Martha K.
PATENT ASSIGNEE(S): University of Vermont and State Agricultural College, USA
SOURCE: PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000078941	A2	20001228	WO 2000-US17245	2000 0622
			<--	
WO 2000078941	A3	20010222		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2375508	AA	20001228	CA 2000-2375508	2000 0622

			<--	
EP 1194168	A2	20020410	EP 2000-943076	2000 0622
			<--	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003503319	T2	20030128	JP 2001-505684	2000 0622
			<--	
AU 780815	B2	20050421	AU 2000-57600	2000 0622
			<--	
AU 2005203138	A1	20050811	AU 2005-203138	2005 0719
			<--	
PRIORITY APPLN. INFO.:			US 1999-140574P P	1999 0623
			<--	
			WO 2000-US17245 W	2000 0622
			<--	

AB The invention is based in part on the discovery that uncoupling proteins (UCPs) are found in the plasma membrane of rapidly dividing cells but not of growth arrested, chemotherapy resistant cells. It has also been found according to the invention that UCP is found in the lysosomal membrane under certain metabolic conditions. Thus the invention is methods, products, screening assays and kits relating to the manipulation of UCP location within cellular and intracellular membranes. One method is to deliver the uncoupling protein as a fusion protein or conjugate with a membrane targeting peptide.

IT **320-67-2**, Azacitidine
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); USES (Uses)
(as inhibitor of plasma membrane uncoupling proteins; subcellular distribution of uncoupling proteins as marker of cell proliferation capacity and its manipulation in tumor therapy)

RN 320-67-2 HCAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM C12N015-00

CC 14-1 (Mammalian Pathological Biochemistry)
Section cross-reference(s): 1

IT Infection
(bacterial, uncoupling proteins and **viral** antigens in **treatment** of; subcellular distribution of uncoupling proteins as marker of cell proliferation capacity and its manipulation in tumor therapy)
IT Parasite
(uncoupling proteins and **viral** antigens in **treatment** of infestation by; subcellular distribution of uncoupling proteins as marker of cell proliferation capacity and its manipulation in tumor therapy)
IT **Infection**
(**viral**, uncoupling proteins and **viral** antigens in **treatment** of; subcellular distribution of uncoupling proteins as marker of cell proliferation capacity and its manipulation in tumor therapy)
IT 50-44-2, 6-Mp 50-89-5, Thymidine, biological studies 50-91-9, Floxuridine 51-20-7, 5-Bromouracil 51-21-8, 5-Fluorouracil 58-96-8, Uridine 65-71-4, Thymine 66-22-8, Uracil, biological studies 71-30-7, Cytosine 120-73-0D, Purine, analogs 146-91-8, GDP 147-94-4, Cytosine arabinoside 154-42-7, 6-Thioguanine 289-95-2D, Pyrimidine, analogs 315-30-0, Allopurinol **320-67-2**, Azacitidine 446-86-6, Azathioprine 504-07-4, Dihydrouracil 554-01-8, 5-Methylcytosine 1820-81-1, 5-Chlorouracil 2022-85-7, 5-Fluorocytosine 2096-10-8, 2-Aminoadenosine 2133-80-4, 8-Azaguanosine 3056-17-5 3868-31-3, 8-Oxoguanosine 3969-27-5, 8-Methoxyadenosine 5536-17-4, Ara-A 7057-53-6, 8-Methoxyguanosine 7481-88-1 10212-20-1, 2'-Fluoro-2'-deoxycytidine 10299-44-2, 8-Azaadenosine 15839-70-0, GDP-fucose 23205-67-6, 8-Fluoroadenosine 25526-93-6, 3'-Fluoro-3'-deoxythymidine 29851-57-8, 8-Oxoadenosine 30516-87-1, AZT 53910-25-1, Deoxycoformycin 59277-89-3, Acyclovir 75607-67-9, Fludarabine phosphate 82410-32-0, Gancyclovir 130272-39-8 134700-29-1, 5-Propynyluracil 151091-68-8, 5-Propynylcytosine 166527-32-8, Guanosine, 8-fluoro- 181427-98-5, GDP-2-fluorofucose 181428-13-7, GDP-β-L-2-aminofucose
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); USES (Uses)
(as inhibitor of plasma membrane uncoupling proteins; subcellular distribution of uncoupling proteins as marker of cell proliferation capacity and its manipulation in tumor therapy)

L73 ANSWER 18 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:666617 HCAPLUS
DOCUMENT NUMBER: 133:232822
TITLE: Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
INVENTOR(S): Molnar-Kimber, Katherine; Toyoizumi, Takane; Kaiser, Larry
PATENT ASSIGNEE(S): The Trustees of the University of Pennsylvania, USA
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2000054795 A1 20000921 WO 1999-US5536
1999
0315
<--
W: AU, CA, JP, US
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
AU 9929051 A1 20001004 AU 1999-29051
1999
0315
<--
US 6428968 B1 20020806 US 1999-435797
1999
1108
<--
PRIORITY APPLN. INFO.: WO 1999-US5536 A
1999
0315
<--

AB The invention includes methods, compns., and kits for killing tumor cells in a subject, e.g. a human patient. The methods comprise administering both a chemotherapeutic agent and an oncolytic virus other than an adenovirus to a subject which has tumor cells. The agent and virus exhibit oncolytic activities that are at least additive, and that may be synergetic. The oncolytic virus may e.g. be a herpes simplex virus (type 1 or 2), a vaccinia virus, a vesicular stomatitis virus, or a Newcastle **disease virus.** The compns. and kits comprise a chemotherapeutic agent and an oncolytic virus other than an adenovirus, either in admixt. or sep.

IT **320-67-2**, Azacitidine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(chemotherapeutic agent-oncolytic virus antitumor combination)

RN 320-67-2 HCAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM A61K038-00
ICS A61K039-395; A01N063-00; C07K001-00

CC 1-6 (**Pharmacology**)
Section cross-reference(s): **63**

IT 50-07-7, Mitomycin C 50-18-0, Cyclophosphamide 50-44-2, 6-Mercaptopurine 50-76-0, Dactinomycin 50-91-9, Floxuridine 51-18-3, Triethylenemelamine 51-21-8, Fluorouracil 51-75-2, Mechlorethamine 51-79-6, Urethan 52-24-4, Triethylenethiophosphoramide 53-79-2, Puromycin 54-25-1, 6-Azauridine 54-91-1, Pipobroman 55-86-7D, Nitrogen mustard, derivs. 55-98-1, Busulfan 57-22-7, Vincristine 59-05-2, Methotrexate 59-30-3D, Folic acid, analogs 66-75-1, Uracil mustard 68-76-8, Triaziquone 69-33-0, Tubercidin 89-38-3, Pteropterin 106-60-5, Aminolevulinic acid 115-02-6, Azaserine

120-73-0D, Purine, analogs 127-07-1, Hydroxyurea 147-94-4, Cytarabine 148-82-3, Melphalan 151-56-4D, Aziridine, derivs., biological studies 154-42-7, Thioguanine 154-93-8, Carmustine 157-03-9 289-95-2D, Pyrimidine, analogs 302-49-8, Uredepa 302-70-5, Mechlorethamine oxide hydrochloride 305-03-3, Chlorambucil **320-67-2**, Azacitidine 459-86-9, Mitoguazone 477-30-5, Demecolcine 488-41-5, Mitobronitol 494-03-1, Chlornaphazine 518-28-5, Podophyllotoxin 545-55-1, Triethylenephosphoramide 555-77-1, 2,2',2''-Trichlorotriethylamine 576-68-1, Mannomustine 642-83-1, Aceglatone 645-05-6, Altretamine 671-16-9, Procarbazine 801-52-5, Porfiromycin 865-21-4, Vinblastine 1017-56-7, Trimethylolmelamine 1402-44-4, Actinomycin F1 1404-15-5, Nogalamycin 1508-45-8 1661-29-6, Meturedepa 1936-40-9, Novembichin 1954-28-5, Etoglucid 1980-45-6, Benzodepa 2608-24-4, Piposulfan 2998-57-4, Estramustine 3094-09-5, Doxifluridine 3546-10-9, Phenesterine 3733-81-1 3778-73-2, Ifosfamide 3819-34-9, Phenamet 3930-19-6, Streptonigrin 4342-03-4, Dacarbazine 4533-39-5, Nitracrine 4803-27-4, Anthramycin 5581-52-2, Thiamiprine 5983-09-5 7440-06-4D, Platinum, compds., biological studies 8052-16-2, Cactinomycin 9014-02-2, Zinostatin 9015-68-3, L-Asparaginase 9050-67-3, Sizofiran 10318-26-0, Mitolactol 10540-29-1, Tamoxifen 11006-70-5, Olivomycin 11056-06-7, Bleomycin 13010-20-3D, Nitrosourea, derivs. 13010-47-4, Lomustine 13311-84-7, Flutamide 13425-98-4, Improsulfan 13452-77-2D, Methylmelamine, derivs. 13494-90-1, Gallium nitrate 13665-88-8, Mopidamol 15663-27-1, Cisplatin 17902-23-7, Tegafur 18378-89-7, Plicamycin 18883-66-4, Streptozocin 20830-81-3, Daunorubicin 21416-67-1, Razoxane 21679-14-1, Fludarabine 22006-84-4, Denopterin 22089-22-1, Trofosfamide 23214-92-8, Doxorubicin 24279-91-2, Carboquone 24280-93-1, Mycophenolic acid 27778-66-1, Tenuazonic acid 29069-24-7, Prednimustine 29767-20-2, Teniposide 31698-14-3, Ancitabine 33069-62-4, Paclitaxel 33419-42-0, Etoposide 35144-64-0D, derivs. 37339-90-5, Lentinan 41575-94-4, Carboplatin 41992-23-8, Spirogermanium 42471-28-3, Nimustine 50264-69-2, Lonidamine 50935-04-1, Carubicin 51264-14-3, Amsacrine 52128-35-5, Trimetrexate 53643-48-4, Vindesine 53910-25-1, Pentostatin 54083-22-6, Zorubicin 54749-90-5, Chlorozotocin 55726-47-1, Enocitabine 56420-45-2, Epirubicin 57998-68-2, Diaziquone 58337-35-2, Elliptinium acetate 58970-76-6, Ubenimex 58994-96-0, Ranimustine 61422-45-5, Carmofur 65271-80-9, Mitoxantrone 66676-88-8, Aclacinomycin 68247-85-8, Peplomycin 70052-12-9, Eflornithine 72496-41-4, Pirarubicin 74913-06-7, Chromomycin 75219-46-4, Bestrabucil 78186-34-2, Bisantrene 92118-27-9, Fotemustine 106486-76-4, Carzinophilin 143831-71-4, Pulmozyme
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(chemotherapeutic agent-oncolytic virus antitumor combination)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L73 ANSWER 19 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:642421 HCAPLUS
DOCUMENT NUMBER: 133:305319
TITLE: Response of foot-and-mouth **disease virus** to increased mutagenesis: influence of viral load and fitness in loss of infectivity
AUTHOR(S): Sierra, Saleta; Davila, Mercedes; Lowenstein, Pedro R.; Domingo, Esteban
CORPORATE SOURCE: Centro de Biologia Molecular Severo Ochoa,

Universidad Autonoma de Madrid, Madrid, 28049, Spain
SOURCE: Journal of Virology (2000), 74(18), 8316-8323
CODEN: JOVIAM; ISSN: 0022-538X
PUBLISHER: American Society for Microbiology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Passage of foot-and-mouth **disease virus** (FMDV) in cell culture in the presence of the mutagenic base analog 5-fluorouracil or 5-azacytidine resulted in decreases of infectivity and occasional extinction of the virus. Low viral loads and low viral fitness enhanced the frequency of extinction events; this finding was shown with a number of closely related FMDV clones and populations differing by ≤106-fold in relative fitness in infections involving either single or multiple passages in the absence or presence of the chemical mutagens. The mutagenic treatments resulted in increases of 2- to 6.4-fold in mutation frequency and ≤3-fold in mutant spectrum complexity. The largest increase observed corresponded to the 3D (polymerase)-coding region, which is highly conserved in nonmutagenized FMDV populations. As a result, nucleotide sequence heterogeneity for the 3D-coding region became very similar to that for the variable VP1-coding region in FMDVs multiply passaged in the presence of chemical mutagens. The results suggest that strategies to combine redns. of viral load and viral fitness could be effectively associated with extinction mutagenesis as a potential new antiviral strategy.

IT **320-67-2**, 5-Azacytidine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(response of foot-and-mouth **disease virus** to increased mutagenesis and influence of viral load and fitness in loss of infectivity in relation to antiviral activity)
RN 320-67-2 HCAPLUS
CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



CC 1-5 (**Pharmacology**)
Section cross-reference(s): 10
ST foot mouth **disease virus** mutagenesis antiviral activity
IT Antiviral agents
Foot-and-mouth **disease virus**
Mutagenesis
Mutagens
Mutation
(response of foot-and-mouth **disease virus** to increased mutagenesis and influence of viral load and fitness in loss of infectivity in relation to antiviral activity)

IT 51-21-8, 5-Fluorouracil **320-67-2**, 5-Azacytidine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(response of foot-and-mouth **disease virus** to increased mutagenesis and influence of viral load and fitness in loss of infectivity in relation to antiviral activity)
REFERENCE COUNT: 63 THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L73 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:98300 HCAPLUS
DOCUMENT NUMBER: 132:132356
TITLE: Chemically induced intracellular hyperthermia for therapeutic and diagnostic use
INVENTOR(S): Bachynsky, Nicholas; Roy, Woodie
PATENT ASSIGNEE(S): Texas Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 149 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000006143	A1	20000210	WO 1999-US16940	1999 0727
				<--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2337690	AA	20000210	CA 1999-2337690	1999 0727
				<--
AU 9951318	A1	20000221	AU 1999-51318	1999 0727
				<--
AU 750313	B2	20020718		
EP 1098641	A1	20010516	EP 1999-935949	1999 0727
				<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRIORITY APPLN. INFO.:			US 1998-94286P P	1998 0727
				<--
			WO 1999-US16940 W	1999 0727
				<--

AB Therapeutic pharmacol. agents and methods are disclosed for chemical

induction of intracellular hyperthermia and/or free radicals for the diagnosis and treatment of infections, malignancy, and other medical conditions. A process and composition are provided for the diagnosis or killing of cancer cells and inactivation of susceptible bacterial, parasitic, fungal, and viral pathogens by chemical generating heat, and/or free radicals and/or hyperthermia-inducible immunogenic determinants by using mitochondrial uncoupling agents, especially 2,4-dinitrophenol, and their conjugates, either alone or in combination with other drugs, hormones, cytokines and radiation.

IT **320-67-2**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(chemical induced intracellular hyperthermia for diagnostic and therapeutic use, and use with other agents)

RN 320-67-2 HCAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM A61K031-06

CC 1-12 (**Pharmacology**)
Section cross-reference(s): 9, **63**

IT **Infection**
(**viral**; chemical induced intracellular hyperthermia for diagnostic and therapeutic use, and use with other agents)

IT 50-18-0 50-49-7 50-65-7 50-76-0, Actinomycin D 51-21-8 51-28-5, biological studies 51-28-5D, derivs. and conjugates 51-48-9, biological studies 51-75-2 52-24-4 53-03-2 53-79-2 54-42-2 55-98-1 56-53-1 56-75-7 56-85-9, L-Glutamine, biological studies 57-22-7 57-62-5 57-63-6 57-92-1, biological studies 58-22-0 58-27-5 59-05-2D, analogs 59-87-0 60-33-3, 9,12-Octadecadienoic acid (9Z,12Z)-, biological studies 60-54-8D, derivs. 61-32-5 61-33-6, biological studies 61-68-7 61-73-4 63-74-1 63-74-1D, derivs. 65-49-6 66-79-5 67-20-9 67-45-8 68-35-9 68-81-5 70-00-8 72-14-0 74-81-7, biological studies 76-43-7 79-43-6D, nitrobenzene derivs 79-57-2 87-86-5 91-40-7 92-82-0D, Phenazine, derivs. 97-18-7 100-02-7, biological studies 102-82-9 103-82-2D, Benzeneacetic acid, derivs. 112-80-1, 9-Octadecenoic acid (9Z)-, biological studies 112-86-7 114-07-8, Erythromycin 116-44-9 125-84-8 126-07-8 127-33-3 147-85-3, L-Proline, biological studies 147-94-4 148-79-8 148-82-3 154-21-2 154-42-7 154-93-8 299-11-6 302-79-4, Retinoic acid 305-03-3 **320-67-2** 370-86-5 389-08-2 439-14-5 443-48-1 459-86-9 463-40-1 479-20-9 484-49-1 506-26-3 506-32-1 518-28-5 519-23-3 520-85-4 521-52-8 527-17-3 529-37-3D, 4(1H)-Quinolinone, derivs. 530-78-9 531-82-8 548-62-9 555-60-2 564-25-0 593-38-4 595-33-5 606-06-4 630-56-8 637-07-0 671-16-9 727-81-1 754-91-6 768-94-5, Tricyclo[3.3.1.13,7]decan-1-amine 804-36-4 865-21-4, Vincaleukoblastine 914-00-1 956-48-9 960-71-4 1041-01-6 1066-17-7, Colistin 1151-51-5 1392-21-8,

Leucomycin 1397-89-3, Amphotericin B 1400-61-9, Nystatin 1402-38-6, Actinomycin 1402-82-0, Amphomycin 1403-17-4, Candicidin 1403-66-3, Gentamicin 1404-04-2, Neomycin 1404-88-2, Tyrothricin 1405-87-4, Bacitracin 1405-97-6, Gramicidin 1406-05-9, Penicillin 1406-11-7, Polymyxin 1689-83-4 1960-88-9 2001-95-8, Valinomycin 2022-85-7 2030-63-9 2034-22-2 2338-10-5 2338-11-6 2338-12-7 2338-29-6 2520-21-0 3056-17-5 3511-16-8 3778-73-2 4151-50-2 4342-03-4 4428-95-9 4543-33-3 5331-91-9 5536-17-4 6217-54-5 6236-05-1 6893-02-3 7283-41-2 7440-43-9, Cadmium, biological studies 7440-70-2, Calcium, biological studies 7481-89-2 7562-61-0 8011-61-8, Tyrocidine 8052-16-2, Actinomycin C 9007-92-5, Glucagon, biological studies 10118-90-8 10417-94-4 10461-11-7 10537-47-0 11000-17-2, Vasopressin 11003-38-6, Capreomycin 11006-76-1, Virginiamycin 11006-78-3, Stendomycin 11017-50-8, Suzukacillin 11029-61-1, Gramicidin A 11056-06-7, Bleomycin 11111-23-2, Lividomycin 11115-82-5, Enduracidin 12633-72-6, Amphotericin 12692-85-2, Antiamebin 13010-47-4 13278-36-9 13311-84-7 13392-28-4 13799-49-0 13799-49-0D, isomers 13909-09-6 13925-12-7 14459-29-1 14698-29-4 15663-27-1 16128-96-4 17090-79-8, Monensin 17650-86-1 17924-92-4 18323-44-9 19246-70-9 19562-30-2 19721-56-3 20559-55-1 22494-42-4 22662-39-1 22916-47-8 25104-18-1 25546-65-0 26097-80-3 26655-39-0 26786-84-5 26787-78-0 27061-78-5, Alamethicin 27138-57-4D, lactone, derivs. 27194-24-7D, derivs. 27314-97-2 27693-70-5 28380-24-7, Nigericin 29767-20-2 30042-37-6 30516-87-1 31441-78-8, Purinethiol 32986-56-4 33069-62-4 33354-58-4 33419-42-0 34368-04-2 36791-04-5 36877-68-6D, derivs. 37231-28-0, Melittin 37517-28-5 38000-06-5 38640-92-5 40451-44-3 41575-94-4 45285-51-6 50892-23-4 51940-44-4 52214-84-3 53024-98-9, Everninomicin 53714-56-0 54965-21-8 55486-00-5 56219-57-9 59277-89-3 60842-45-7, Desaspidin 60976-67-2, Gramicidin J 61477-96-1 62362-59-8 63939-09-3, Curamycin 65277-42-1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(chemical induced intracellular hyperthermia for diagnostic and therapeutic use, and use with other agents)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L73 ANSWER 21 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:25982 HCAPLUS
DOCUMENT NUMBER: 130:61105
TITLE: Pharmaceutical composition and method using N-phosphonoglycine derivatives for inhibiting the growth of cancers and **treatment** of **viral infections**
INVENTOR(S): Camden, James Berger
PATENT ASSIGNEE(S): The Procter & Gamble Company, USA
SOURCE: U.S., 7 pp., Cont.-in-part of U.S. 5,665,713. CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5854231	A	19981229	US 1996-680469	1996 0715

			<--	
US 5665713	A	19970909	US 1995-420940	
				1995
				0412
			<--	
ZA 9602880	A	19970317	ZA 1996-2880	
				1996
				0411
			<--	
US 5902804	A	19990511	US 1997-802653	
				1997
				0218
			<--	
US 6090796	A	20000718	US 1998-220914	
				1998
				1224
			<--	

PRIORITY APPLN. INFO.:	US 1995-420940	A2
		1995
		0412
	<--	
	US 1995-1840P	P
		1995
		0803
	<--	
	US 1996-680469	A1
		1996
		0715
	<--	

OTHER SOURCE(S): MARPAT 130:61105

AB A pharmaceutical composition is disclosed that inhibits the growth of cancers and tumors in mammals, particularly in human and warm-blooded animals. The composition contains N-phosphonoglycine derivs. which are systemic herbicides in combination with chemotherapeutic agents for treatment of cancers and tumors. N-phosphonoglycine derivs. can be used to **treat viral infections**, particularly herpes infections. Optionally potentiators can be included.

IT **320-67-2**, Azacytidine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(phosphonoglycine derivs. and combinations for treatment of cancer and **viral infections**)

RN 320-67-2 HCAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM A61K031-66
INCL 514076000
CC 1-12 (**Pharmacology**)
Section cross-reference(s): **63**
IT Drug delivery systems

(enteric; phosphonoglycine derivs. and combinations for treatment of cancer and **viral infections**)
IT Drug delivery systems
(injections, i.v.; phosphonoglycine derivs. and combinations for treatment of cancer and **viral infections**
)
IT Drug delivery systems
(oral; phosphonoglycine derivs. and combinations for treatment of cancer and **viral infections**)
IT Antitumor agents
Antiviral agents
Chemotherapy
Drug delivery systems
Drug interactions
Herpesviridae
Human herpesvirus 2
(phosphonoglycine derivs. and combinations for treatment of cancer and **viral infections**)
IT Drug delivery systems
(solids; phosphonoglycine derivs. and combinations for treatment of cancer and **viral infections**)
IT Herbicides
(systemic; phosphonoglycine derivs. and combinations for treatment of cancer and **viral infections**)
IT Drug delivery systems
(unit doses; phosphonoglycine derivs. and combinations for treatment of cancer and **viral infections**)
IT 50-18-0, Cyclophosphamide 50-76-0, Dactinomycin 50-91-9 51-21-8, Fluorouracil 56-40-6D, Glycine, N-phosphono derivs., biological studies 59-05-2, Methotrexate 127-07-1, Hydroxyurea 147-94-4, Cytarabine 154-42-7, 6-Thioguanine **320-67-2**, Azacytidine 645-05-6, Altretamine 1071-83-6, N-(Phosphonomethyl)glycine 1071-83-6D, N-(Phosphonomethyl)glycine, lower alkyl amine salts 6112-76-1, Purine-6-thiol monohydrate 9015-68-3, Asparaginase 11056-06-7, Bleomycin 15663-27-1, Cisplatin 18378-89-7, Plicamycin 21679-14-1, Fludarabine 23214-92-8, Doxorubicin 23249-97-0, Procodazole 29767-20-2, Teniposide 33419-42-0, Etoposide 38641-94-0, N-(Phosphonomethyl)glycine isopropylamine salt 53910-25-1, Pentostatin 59277-89-3, Acyclovir 76849-19-9, CB3717 216252-30-1, Cyctrabine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(phosphonoglycine derivs. and combinations for treatment of cancer and **viral infections**)
REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L73 ANSWER 22 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:813715 HCAPLUS
DOCUMENT NUMBER: 130:57175
TITLE: TXU-7-pokeweed antiviral protein immunotoxin and antiviral and antitumor uses thereof
INVENTOR(S): Uckun, Faith M.
PATENT ASSIGNEE(S): Regents of the University of Minnesota, USA
SOURCE: PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 9855150 A1 19981210 WO 1998-US11287
1998
0603
<--

W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

US 6372217 B1 20020416 US 1998-14028
1998
0127
<--

CA 2292426 AA 19981210 CA 1998-2292426
1998
0603
<--

AU 9877188 A1 19981221 AU 1998-77188
1998
0603
<--

EP 996467 A1 20000503 EP 1998-925178
1998
0603
<--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

JP 2002511753 T2 20020416 JP 1999-502746
1998
0603
<--

PRIORITY APPLN. INFO.: US 1997-48364P P
1997
0603
<--

US 1998-14028 A2
1998
0127
<--

WO 1998-US11287 W
1998
0603
<--

AB Immunotoxins comprising the monoclonal antibody TXU-7 linked to an amount of pokeweed antiviral protein are provided which are effective for the treatment of T-cell leukemias, lymphomas, acute myeloid leukemias and **viral infections**, e.g., HIV infection.

IT **320-67-2**, 5-Azacytidine
RL: PEP (Physical, engineering or chemical process); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); USES (Uses)
(TXU-7-pokeweed antiviral protein immunotoxin and antiviral and antitumor uses thereof)

RN 320-67-2 HCAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC A61K047-48
CC 63-5 (**Pharmaceuticals**)
Section cross-reference(s): **1**, 15
IT 50-18-0, Cyclophosphamide 50-91-9, Floxuridine 51-21-8, 5 Fluorouracil 59-05-2, Methotrexate 147-94-4, Cytarabine 154-42-7, Thioguanine **320-67-2**, 5-Azacytidine 4291-63-8, 2-Chlorodeoxyadenosine 30516-87-1, Zidovudine 31441-78-8, Mercaptopurine 52128-35-5, Trimetrexate
RL: PEP (Physical, engineering or chemical process); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); USES (Uses)
(TXU-7-pokeweed antiviral protein immunotoxin and antiviral and antitumor uses thereof)
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L73 ANSWER 23 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:764282 HCAPLUS
DOCUMENT NUMBER: 130:20546
TITLE: HIV and cancer treatment
INVENTOR(S): Camden, James Berger
PATENT ASSIGNEE(S): The Procter & Gamble Company, USA
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9851303	A1	19981119	WO 1997-US21564	1997 1126
			<--	
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9709095	A	19980511	ZA 1997-9095	1997 1010
			<--	
CA 2268848	AA	19981119	CA 1997-2268848	1997 1126
			<--	

AU 9874029	A1	19981208	AU 1998-74029	1997 1126 <--
EP 954309	A1	19991110	EP 1997-949599	1997 1126 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
BR 9712981	A	20000418	BR 1997-12981	1997 1126 <--
CN 1254281	A	20000524	CN 1997-182189	1997 1126 <--
JP 2000510156	T2	20000808	JP 1998-522997	1997 1126 <--
NO 9901701	A	20000117	NO 1999-1701	1999 0409 <--
KR 2000049064	A	20000725	KR 1999-703137	1999 0410 <--
PRIORITY APPLN. INFO.:			US 1997-46726P P	1997 0516 <--
			WO 1997-US21564 W	1997 1126 <--

AB A method of treating HIV or other **viral infections** by administering a herbicide or fungicide or derivative thereof to an animal or human. The fungicides or herbicides can be used in conjunction with other treatments, e.g. with AZT or protease inhibitors for the treatment of HIV. For example, thiabendazole and chloropropham have been shown to quickly reduce the level of virus production from cell populations chronically infected with HIV-1 and the antiviral effect is maintained with continued compound exposure. This reduction of virus production occurs at concns. which are non toxic to the host cell and which have no effect on the syntheses of cellular DNA, RNA and protein. Further, chronically infected cells treated for prolonged periods of time with thiabendazole and chloropropham were not super-infected with HIV. A method for inhibiting the growth of tumors and cancers in mammals comprising administering a herbicidal or fungicidal derivative is also disclosed herein. The fungicides or herbicides can be used in conjunction with other treatments, e.g. taxol for the treatment of breast cancer. Potentiators can also be included in the herbicidal or fungicidal composition This method is particularly effective when the cancer or virus is an animal cell genetically modified by plant or fungus genetic material. A chemotherapeutic agent can also be administered first to significantly reduce the size of the cancer and then the treatment with the herbicide or fungicide is used. These methods are particularly effective when the cancer or virus is a mutated cell comprising plant or fungal genetic material.

IT **320-67-2**, Azacytidine
RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(therapy of cancer and **viral infections** with drugs in combination with fungicides and herbicides)
RN 320-67-2 HCAPLUS
CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM A61K031-41
ICS A61K031-415; A61K031-66
CC 1-5 (**Pharmacology**)
IT Intestine, neoplasm
(colon, inhibitors; therapy of cancer and **viral infections** with drugs in combination with fungicides and herbicides)
IT Antitumor agents
(colon; therapy of cancer and **viral infections** with drugs in combination with fungicides and herbicides)
IT Lung, neoplasm
(inhibitors; therapy of cancer and **viral infections** with drugs in combination with fungicides and herbicides)
IT Antitumor agents
(leukemia; therapy of cancer and **viral infections** with drugs in combination with fungicides and herbicides)
IT Drug delivery systems
(liposomes; therapy of cancer and **viral infections** with drugs in combination with fungicides and herbicides)
IT Antitumor agents
(lung; therapy of cancer and **viral infections** with drugs in combination with fungicides and herbicides)
IT Antitumor agents
(mammary gland; therapy of cancer and **viral infections** with drugs in combination with fungicides and herbicides)
IT Antitumor agents
(melanoma; therapy of cancer and **viral infections** with drugs in combination with fungicides and herbicides)
IT Mammary gland
(neoplasm, inhibitors; therapy of cancer and **viral infections** with drugs in combination with fungicides and herbicides)
IT Antitumor agents
Antiviral agents
Fungicides
Herbicides
Human immunodeficiency virus 1
(therapy of cancer and **viral infections** with drugs in combination with fungicides and herbicides)

IT 144114-21-6, Retropepsin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; therapy of cancer and **viral infections** with drugs in combination with fungicides and herbicides)
IT 50-18-0, Cyclophosphamide 50-44-2, 6-Mercaptopurine 50-76-0, Dactinomycin 50-91-9 51-17-2, Benzimidazole 51-21-8, Fluorouracil 59-05-2, Methotrexate 101-21-3, Chloropropham 126-07-8, Griseofulvin 127-07-1, Hydroxyurea 147-94-4, Cytarabine 148-79-8 154-42-7, 6-Thioguanine **320-67-2**, Azacytidine 645-05-6, Altretamine 768-94-5, Amantadine 1071-83-6 9015-68-3, Asparaginase 10605-21-7 11056-06-7, Bleomycin 15663-27-1, Cisplatin 17804-35-2, Benomyl 18378-89-7, Plicamycin 21679-14-1, Fludarabine 23214-92-8, Doxorubicin 25316-40-9, Adriamycin 29767-20-2, Teniposide 30516-87-1, 3'-Azido-3'-deoxythymidine 33069-62-4, Taxol 33419-42-0, Etoposide 34435-09-1, A-36683 53910-25-1, Pentostatin 60207-90-1, Propiconazole 76849-19-9, CB3717 86386-73-4, Fluconazole 125317-39-7, Navelbine 216252-30-1, Cyctrabine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(therapy of cancer and **viral infections** with drugs in combination with fungicides and herbicides)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L73 ANSWER 24 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:244346 HCAPLUS
DOCUMENT NUMBER: 126:220704
TITLE: Use of fluconazole for inhibiting the growth of cancers
INVENTOR(S): Camden, James Berger
PATENT ASSIGNEE(S): Procter and Gamble Company, USA
SOURCE: PCT Int. Appl., 11 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9705873	A2	19970220	WO 1996-US12474	1996 0730
			<--	
WO 9705873	A3	19970327		
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA				
US 5908855	A	19990601	US 1996-674180	1996 0716
			<--	
CA 2229024	AA	19970220	CA 1996-2229024	1996 0730

<--

AU 9666833	A1	19970305	AU 1996-66833	1996 0730
			<--	
AU 711966	B2	19991028		
EP 841921	A2	19980520	EP 1996-926806	1996 0730
			<--	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
CN 1195288	A	19981007	CN 1996-196682	1996 0730
			<--	
BR 9609966	A	19990202	BR 1996-9966	1996 0730
			<--	
JP 11510187	T2	19990907	JP 1996-508494	1996 0730
			<--	
NZ 315184	A	20000526	NZ 1996-315184	1996 0730
			<--	
NZ 503921	A	20020301	NZ 1996-503921	1996 0730
			<--	
ZA 9606529	A	19970916	ZA 1996-6529	1996 0801
			<--	
NO 9800473	A	19980403	NO 1998-473	1998 0203
			<--	
PRIORITY APPLN. INFO.:			US 1995-1889P P	1995 0804
			<--	
			US 1996-674180 A	1996 0716
			<--	
			NZ 1996-315184 A1	1996 0730
			<--	
			WO 1996-US12474 W	1996 0730
			<--	

AB A pharmaceutical composition for the treatment of cancers or tumors in mammals is disclosed which comprises 2-(2,4-difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol (fluconazole) and its derivs. A chemotherapeutic agent can be used in conjunction with fluconazole and its derivs. as potentiator. Fluconazole and its derivs. can also be used to **treat viral infections**, either alone, in conjunction with other anti-viral agents or with a potentiator. Fluconazole at concentration of 50.0 μg/mL was effective against human lung and ovarian cancers.

IT **320-67-2**, Azacitidine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(use of fluconazole for inhibiting growth of cancers)
RN 320-67-2 HCAPLUS
CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM A61K031-41
CC 1-6 (**Pharmacology**)
Section cross-reference(s): **63**
IT **Infection**
(**viral**; use of fluconazole for inhibiting growth of cancers)
IT 50-18-0, Cyclophosphamide 50-44-2, Mercaptopurine 50-76-0, Dactinomycin 50-91-9 51-21-8, Fluorouracil 59-05-2, Methotrexate 127-07-1, Hydroxyurea 147-94-4, Cytarabine 154-42-7, 6-Thioguanine **320-67-2**, Azacitidine 645-05-6, Altretamine 9015-68-3, Asparaginase 11056-06-7, Bleomycin 15663-27-1, Cisplatin 23214-92-8 29767-20-2, Teniposide 33069-62-4, Taxol 33419-42-0, Etoposide 53910-25-1, Pentostatin 75607-67-9, Fludarabine 76849-19-9, Cb3717 86386-73-4, Fluconazole
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(use of fluconazole for inhibiting growth of cancers)

L73 ANSWER 25 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:244345 HCAPLUS
DOCUMENT NUMBER: 126:220703
TITLE: Use of 1H-1,2,4-triazole derivatives for inhibiting the growth of cancers
INVENTOR(S): Camden, James Berger
PATENT ASSIGNEE(S): Procter and Gamble Company, USA
SOURCE: PCT Int. Appl., 12 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9705872	A2	19970220	WO 1996-US12473	19960730
			<--	
WO 9705872	A3	19970327		

W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP,

KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR,
TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
CM, GA

US 6200992	B1	20010313	US 1996-674182	1996 0716 <--
CA 2228502	AA	19970220	CA 1996-2228502	1996 0730 <--
AU 9666832	A1	19970305	AU 1996-66832	1996 0730 <--
AU 709007	B2	19990819		
EP 841920	A2	19980520	EP 1996-926805	1996 0730 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,
PT, IE, FI

CN 1192142	A	19980902	CN 1996-196038	1996 0730 <--
BR 9609987	A	19990112	BR 1996-9987	1996 0730 <--
JP 11510186	T2	19990907	JP 1996-508493	1996 0730 <--
ZA 9606530	A	19970611	ZA 1996-6530	1996 0803 <--
NO 9800419	A	19980402	NO 1998-419	1998 0130 <--
US 6110953	A	20000829	US 1999-245520	1999 0205 <--
US 2001047015	A1	20011129	US 2000-737835	2000 1215 <--

PRIORITY APPLN. INFO.:	US 1995-1838P	P	1995 0803 <--
	US 1996-674182	A	1996 0716 <--
	US 1995-473819	A1	1995 0607 <--
	WO 1996-US12473	W	

1996
0730

<--

OTHER SOURCE(S): MARPAT 126:220703

AB A pharmaceutical composition that inhibits the growth of tumors and cancers in mammals comprises a 1H-1,2,4-triazole derivative (Markush structure given) along with a safe and effective amount of a chemotherapeutic agent. Potentiators, e.g. tripolidine, can also be used to enhance the effectiveness of the drugs. The triazole and potentiator compds. can also be used to **treat viral infections.** Propiconazole at concentration of 50.0 μg/mL was effective against human colon and lung melanoma and ovarian cancer in vitro.

IT **320-67-2**, Azacitidine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(use of triazole derivs. for inhibiting growth of cancers)

RN 320-67-2 HCAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM A61K031-41

CC 1-6 (**Pharmacology**)

IT 50-18-0, Cyclophosphamide 50-44-2, Mercaptopurine 50-76-0, Dactinomycin 50-91-9 51-21-8, Fluorouracil 59-05-2, Methotrexate 127-07-1, Hydroxyurea 147-94-4, Cytarabine 154-42-7, 6-Thioguanine 288-88-0D, 1H-1,2,4-Triazole, derivs. **320-67-2**, Azacitidine 645-05-6, Altretamine 9015-68-3, Asparaginase 11056-06-7, Bleomycin 15663-27-1, Cisplatin 18378-89-7, Plicamycin 23214-92-8 29767-20-2, Teniposide 33419-42-0, Etoposide 53910-25-1, Pentostatin 60207-31-0 60207-35-4 60207-90-1, Propiconazole 60207-93-4 60207-97-8 75607-67-9, Fludarabine 76849-19-9, Cb3717
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(use of triazole derivs. for inhibiting growth of cancers)

L73 ANSWER 26 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1997:226942 HCAPLUS

DOCUMENT NUMBER: 126:216642

TITLE: Use of griseofulvin for inhibiting the growth of cancers

INVENTOR(S): Camden, James Berger

PATENT ASSIGNEE(S): Procter & Gamble Company, USA

SOURCE: PCT Int. Appl., 11 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9705870	A2	19970220	WO 1996-US12475	1996 0730 <--
WO 9705870	A3	19970417		
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA				
CA 2228503	AA	19970220	CA 1996-2228503	1996 0730 <--
AU 9666834	A1	19970305	AU 1996-66834	1996 0730 <--
AU 713031	B2	19991118		
EP 841914	A2	19980520	EP 1996-926807	1996 0730 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
BR 9609920	A	19990706	BR 1996-9920	1996 0730 <--
JP 11511136	T2	19990928	JP 1996-508495	1996 0730 <--
ZA 9606583	A	19970219	ZA 1996-6583	1996 0802 <--
NO 9800420	A	19980403	NO 1998-420	1998 0130 <--
PRIORITY APPLN. INFO.:			US 1995-1839P P	1995 0803 <--
			US 1996-674181 A	1996 0716 <--
			WO 1996-US12475 W	1996 0730 <--

AB A pharmaceutical composition for the treatment of cancers or tumors in mammals is disclosed which comprises griseofulvin. A chemotherapeutic agent can be used in conjunction with griseofulvin as can potentiators. Griseofulvin can also be used to **treat viral infections**, either alone, in conjunction with other viral agents or with a potentiator.

IT **320-67-2**, Azacytidine
RL: MOA (Modifier or additive use); **THU (Therapeutic use)** ; BIOL (Biological study); USES (Uses)
(griseofulvin for inhibiting the growth of cancers)
RN 320-67-2 HCAPLUS
CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM A61K031-34
CC 63-5 (**Pharmaceuticals**)
Section cross-reference(s): **1**
IT 50-18-0, Cyclophosphamide 50-44-2, 6-Mercaptopurine 50-76-0, Dactinomycin 50-91-9 51-21-8, 5-FU 59-05-2, Methotrexate 127-07-1, Hydroxyurea 147-94-4, Cytarabine 154-42-7, 6-Thioguanine **320-67-2**, Azacytidine 645-05-6, Altretamine 9015-68-3, Asparaginase 11056-06-7, Bleomycin 15663-27-1, Cisplatin 21679-14-1, Fludarabine 23214-92-8 29767-20-2, Teniposide 33419-42-0, Etoposide 53910-25-1, Pentostatin 76849-19-9, CB3717
RL: MOA (Modifier or additive use); **THU (Therapeutic use)** ; BIOL (Biological study); USES (Uses)
(griseofulvin for inhibiting the growth of cancers)

=>